{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1576,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":1576,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"38079aa63b5f","filters":{"topic":"HIV/AIDS drug development and treatment"}},"results":[{"id":"W2147458973","doi":"10.1038/nrd4010","title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Ligue Contre le Cancer; Olav Raagholt og Gerd Meidel Raagholts stiftelse; Association pour la Recherche sur le Cancer","keywords":"Nucleoside; Medicine; Cancer; Drug development; Nucleoside analogue; Cancer treatment; Cancer therapy; Drug; Computational biology; Pharmacology; Biology; Internal medicine; Genetics","authors":[{"name":"Lars Petter Jordheim","is_ca":true},{"name":"David Durantel","is_ca":false},{"name":"Fabien Zoulim","is_ca":false},{"name":"Charles Dumontet","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02570177930017246,"gpt":0.3578543889485624,"spread":0.3321526096483899,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009686204,0.001091688,0.001739184,0.002373097,0.0003725498,0.001030483,0.00108365,0.001156605,0.004731175],"category_scores_gemma":[0.001014209,0.0003828006,0.0006551507,0.002484866,0.000734295,0.001478028,0.0009584305,0.00266836,0.002747827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006981671,"about_ca_system_score_gemma":0.001125924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001175291,"about_ca_topic_score_gemma":0.002807985,"domain_scores_codex":[0.9996995,0.00005146791,0.00003088765,0.00004425,0.0001404728,0.00003344246],"domain_scores_gemma":[0.9994425,0.000295856,0.00006962111,0.00001824722,0.0001243631,0.00004941166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001088171,0.0001206763,0.0001400763,0.01267312,0.00007807966,0.0002028331,0.00004625516,0.0006386774,0.006292106,0.00567726,0.01830443,0.9557176],"study_design_scores_gemma":[0.00003906597,0.000164267,0.0004199408,0.00125232,0.0001036786,0.0008535171,0.00003249443,0.0001950233,0.00189393,0.002363961,0.9926576,0.00002418644],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001812247,0.9975564,0.0004192053,0.000219666,0.0001764531,0.000007454202,0.00002299926,0.00001276057,0.001403705],"genre_scores_gemma":[0.001003263,0.9974861,0.0005275498,0.0001761721,0.0001421842,0.000006547361,0.00003319214,0.00000225955,0.0006226969],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004731175,"threshold_uncertainty_score":0.01582736,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122280827","doi":"10.1001/jama.296.7.827","title":"Treatment for Adult HIV Infection","year":2006,"lang":"en","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1037,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Antiretroviral therapy; Ritonavir; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Intensive care medicine; MEDLINE; Human immunodeficiency virus (HIV); Family medicine; Immunology; Viral load","authors":[{"name":"Scott M. Hammer","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Robert T. Schooley","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"Melanie Thompson","is_ca":false},{"name":"Charles C. J. Carpenter","is_ca":false},{"name":"Margaret A. Fischl","is_ca":false},{"name":"Brian Gazzard","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Douglas D. Richman","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Paul A. Volberding","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01152513169205912,"gpt":0.2615392131010178,"spread":0.2500140814089587,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399482,0.0002536604,0.0004524965,0.0007604854,0.0005857961,0.0007207119,0.0005472474,0.0008363122,0.05547752],"category_scores_gemma":[0.006370391,0.00009031354,0.0004234488,0.001071815,0.0002324256,0.0006634842,0.000876514,0.001219612,0.01037007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006201438,"about_ca_system_score_gemma":0.002255876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001463291,"about_ca_topic_score_gemma":0.002542453,"domain_scores_codex":[0.9986145,0.0005504694,0.0002322889,0.0001455252,0.0003560538,0.0001011045],"domain_scores_gemma":[0.9983759,0.0004272786,0.0004364304,0.0001062405,0.0004474211,0.0002067667],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002789627,0.0001198485,0.009764652,0.003126356,0.00007142681,0.0004079955,0.0002392148,0.00004184454,0.0002459392,0.002832066,0.582743,0.4001286],"study_design_scores_gemma":[0.000205469,0.0002332291,0.01964418,0.005717953,0.00006422614,0.000958987,0.0001785058,0.00006619207,0.0001220841,0.00170364,0.9710937,0.0000119592],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"review","genre_scores_codex":[0.02380266,0.2696986,0.006367971,0.103798,0.01865046,0.007815122,0.04679462,0.0006941407,0.5223784],"genre_scores_gemma":[0.2366031,0.2465319,0.03038716,0.1814917,0.01754956,0.02216624,0.05052823,0.0002183029,0.2145237],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.05547752,"threshold_uncertainty_score":0.1855908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133315239","doi":"10.1001/jama.283.3.381","title":"Antiretroviral Therapy in Adults","year":2000,"lang":"en","type":"review","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1036,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Interim; Antiretroviral therapy; Intensive care medicine; Clinical trial; Clinical research; Human immunodeficiency virus (HIV); MEDLINE; ANTIRETROVIRAL AGENTS; Alternative medicine; Family medicine; Viral load; Pathology","authors":[{"name":"Charles C. J. Carpenter","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Margaret A. Fischl","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Brian Gazzard","is_ca":false},{"name":"Scott M. Hammer","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Douglas D. Richman","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Robert T. Schooley","is_ca":false},{"name":"Melanie Thompson","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Paul A. Volberding","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02841402617113739,"gpt":0.3167798492283666,"spread":0.2883658230572292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009207065,0.0008917293,0.001455517,0.001093762,0.0002629175,0.0007923937,0.0007900891,0.001263496,0.01161284],"category_scores_gemma":[0.002343537,0.0001604309,0.0005568885,0.001225649,0.0002261034,0.0008430552,0.0006322095,0.001490747,0.008473817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003489948,"about_ca_system_score_gemma":0.001446078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001232936,"about_ca_topic_score_gemma":0.002042659,"domain_scores_codex":[0.9993414,0.0002090898,0.0001264773,0.00006145511,0.000216771,0.00004468845],"domain_scores_gemma":[0.9994125,0.0002030417,0.0001714945,0.00002831328,0.0001408408,0.00004382546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008724285,0.00005002182,0.0004077905,0.009756629,0.00008821595,0.0002072702,0.00005599155,0.00006251553,0.0002978126,0.001331965,0.1294558,0.8581988],"study_design_scores_gemma":[0.0000741543,0.00006679813,0.001175649,0.01081862,0.0001410211,0.001219682,0.00003385245,0.00002988266,0.0001320847,0.0006391212,0.9856613,0.000007939607],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002094565,0.9846511,0.0002498906,0.002237521,0.002105163,0.00004761097,0.0001504427,0.00003417038,0.01031466],"genre_scores_gemma":[0.002408197,0.9848221,0.0008678545,0.005181942,0.001528339,0.0001004684,0.0003821775,0.000006197416,0.004702786],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01161284,"threshold_uncertainty_score":0.03884882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2109046728","doi":"10.1371/journal.pone.0004724","title":"Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":960,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Drug resistance; HIV drug resistance; Resistance mutation; Drug; Mutation; Virology; Medicine; Resistance (ecology); Human immunodeficiency virus (HIV); Biology; Genetics; Pharmacology; Antiretroviral therapy; Gene; Viral load; Reverse transcriptase; Polymerase chain reaction","authors":[{"name":"Diane Bennett","is_ca":false},{"name":"Ricardo Camacho","is_ca":false},{"name":"Dan Oţelea","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Hervé Fleury","is_ca":false},{"name":"Mark Kiuchi","is_ca":false},{"name":"Walid Heneine","is_ca":false},{"name":"Rami Kantor","is_ca":false},{"name":"Michael R. Jordan","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"Charles A. Boucher","is_ca":false},{"name":"David van de Vijver","is_ca":false},{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"Tommy F. Liu","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0173285574361156,"gpt":0.2399108085780483,"spread":0.2225822511419327,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00608601,0.0007003272,0.001017325,0.003523136,0.0004830968,0.001599412,0.002361156,0.001931658,0.002806364],"category_scores_gemma":[0.009422065,0.0004449674,0.0006956798,0.002145711,0.000459404,0.001935455,0.001068284,0.002020694,0.001703345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00161491,"about_ca_system_score_gemma":0.00335089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01499528,"about_ca_topic_score_gemma":0.0278146,"domain_scores_codex":[0.9976332,0.0005100856,0.0006822703,0.0001913284,0.0008689896,0.0001140191],"domain_scores_gemma":[0.9843262,0.001819919,0.00148396,0.0006104151,0.01089376,0.0008656957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0001433885,0.0002041225,0.02622279,0.0008552229,0.00005877549,0.0005417962,0.0002775938,0.0005821633,0.003275976,0.001730979,0.3054768,0.6606305],"study_design_scores_gemma":[0.00009303007,0.0002385894,0.07703644,0.001438406,0.0001602962,0.004014797,0.000223211,0.002351464,0.004052336,0.0005759133,0.9097495,0.00006602648],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1406962,0.2536351,0.1353782,0.2365167,0.03838142,0.004949898,0.04927611,0.006750703,0.1344157],"genre_scores_gemma":[0.190785,0.2202333,0.4043065,0.05725303,0.01168177,0.002183761,0.06303931,0.001269325,0.04924794],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01499528,"threshold_uncertainty_score":0.03218627,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133649749","doi":"10.1056/nejmoa035026","title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":915,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia","funders":"Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Enfuvirtide; Regimen; Medicine; Viral load; Internal medicine; Liter; Virology; Randomization; Drug resistance; Dolutegravir; Human immunodeficiency virus (HIV); Randomized controlled trial; Immunology; Gastroenterology; Antiretroviral therapy; Biology; Gp41; Microbiology","authors":[{"name":"Jacob Lalezari","is_ca":false},{"name":"Keith Henry","is_ca":false},{"name":"Mary O’Hearn","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Peter J. Piliero","is_ca":false},{"name":"Benoît Trottier","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Calvin Cohen","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Jain Chung","is_ca":false},{"name":"Ralph DeMasi","is_ca":false},{"name":"Lucille Donatacci","is_ca":false},{"name":"Claude Drobnes","is_ca":false},{"name":"John Delehanty","is_ca":false},{"name":"Miklos Salgo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01274361375654826,"gpt":0.2547374387986145,"spread":0.2419938250420663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006447487,0.0003143109,0.0005577549,0.0002000665,0.0004094648,0.0002894193,0.0003180896,0.0003460282,0.002922326],"category_scores_gemma":[0.0005775179,0.0002212353,0.0003696233,0.000264529,0.0004479252,0.0002735946,0.0002911371,0.0006175982,0.000188344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007277272,"about_ca_system_score_gemma":0.001646909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006738074,"about_ca_topic_score_gemma":0.02687872,"domain_scores_codex":[0.9997696,0.0001310342,0.00001362396,0.00002886856,0.00002132773,0.00003550429],"domain_scores_gemma":[0.9996318,0.00009643141,0.00006673948,0.00001321674,0.00002544022,0.0001665062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3360467,0.02450738,0.2398946,0.002850945,0.003005969,0.001307886,0.001711011,0.002129667,0.06061485,0.0008425976,0.009898124,0.3171903],"study_design_scores_gemma":[0.2495323,0.1162717,0.6070517,0.0004003943,0.002305723,0.001664618,0.001040827,0.00118689,0.003690637,0.0006685054,0.01611556,0.00007109867],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926895,0.004405051,0.0001921016,0.0006717529,0.00003438851,0.0005281237,0.0002245786,0.000009930988,0.001244399],"genre_scores_gemma":[0.9919049,0.004430994,0.0008218294,0.0009551202,0.00006666932,0.0007267446,0.0003193704,0.000005549727,0.0007688496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006738074,"threshold_uncertainty_score":0.01339769,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2094241860","doi":"10.1056/nejmoa1215541","title":"Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Dolutegravir; Abacavir; Medicine; Lamivudine; Virology; Integrase inhibitor; Regimen; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Internal medicine; Viral load; Hepatitis B virus","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Antonio Antela","is_ca":false},{"name":"Nathan Clumeck","is_ca":false},{"name":"Dan Duiculescu","is_ca":false},{"name":"Andrea Eberhard","is_ca":false},{"name":"Félix Gutiérrez","is_ca":false},{"name":"Laurent Hocqueloux","is_ca":false},{"name":"Franco Maggiolo","is_ca":false},{"name":"Uriel Sandkovsky","is_ca":false},{"name":"Catherine Granier","is_ca":false},{"name":"Keith A. Pappa","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Sherene Min","is_ca":false},{"name":"Garrett Nichols","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02589605435681262,"gpt":0.2881361588825451,"spread":0.2622401045257324,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007674844,0.0002734626,0.0008816041,0.0002067471,0.0002125768,0.0002300867,0.0003604045,0.0002888418,0.004365552],"category_scores_gemma":[0.0006602441,0.0001444636,0.0003867956,0.0002320249,0.0002495183,0.0001976381,0.0002150054,0.0007408642,0.000418354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000361937,"about_ca_system_score_gemma":0.0006945897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004929007,"about_ca_topic_score_gemma":0.001763286,"domain_scores_codex":[0.9997063,0.0001374142,0.00002992658,0.0000414928,0.00005082393,0.00003401047],"domain_scores_gemma":[0.999826,0.00005180769,0.00003701978,0.00001016586,0.00001244357,0.00006254316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3008948,0.01423928,0.01562147,0.004315915,0.001620243,0.0003786941,0.0002714682,0.002182381,0.03537667,0.0006068858,0.006051465,0.6184406],"study_design_scores_gemma":[0.5540404,0.2972127,0.08749681,0.0008807546,0.001643955,0.002757803,0.0001759702,0.002914776,0.009721179,0.001007188,0.04208947,0.00005881866],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667012,0.02191109,0.001139233,0.0008372685,0.0001861667,0.002583706,0.00104727,0.00009447047,0.005499588],"genre_scores_gemma":[0.9870908,0.006002839,0.00261744,0.0007102445,0.0001799211,0.0009971035,0.0005459408,0.000008031586,0.001847708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004365552,"threshold_uncertainty_score":0.01460427,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099697190","doi":"10.1001/jama.283.18.2417","title":"Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":783,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Drug resistance; Intensive care medicine; Human immunodeficiency virus (HIV); HIV drug resistance; Antiretroviral therapy; MEDLINE; Viral load; Immunology","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02896580900075403,"gpt":0.2595900500640946,"spread":0.2306242410633406,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03157628,0.001662673,0.001400012,0.004718396,0.00200803,0.002015976,0.004496358,0.009515764,0.004557448],"category_scores_gemma":[0.03761317,0.001066039,0.002473389,0.004356233,0.001474522,0.002529684,0.002458313,0.009674757,0.003611257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001719007,"about_ca_system_score_gemma":0.01495168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01052907,"about_ca_topic_score_gemma":0.01430306,"domain_scores_codex":[0.9828851,0.008036477,0.003927708,0.0004568148,0.003879265,0.0008145621],"domain_scores_gemma":[0.9350124,0.01258088,0.005162353,0.001274508,0.0413319,0.004637823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001145753,0.0002597916,0.00561175,0.002143468,0.00007572857,0.0005616071,0.0005134388,0.0003548789,0.0007980889,0.0007848005,0.8162858,0.1724962],"study_design_scores_gemma":[0.0002022557,0.0002279237,0.02066217,0.01088034,0.0002947133,0.001332226,0.00106411,0.0007373815,0.0009562275,0.002284926,0.9612602,0.00009755619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.007439777,0.1501141,0.02081905,0.7049068,0.0334472,0.008656467,0.005843388,0.0008919715,0.06788119],"genre_scores_gemma":[0.0663565,0.2573642,0.2699733,0.2795178,0.02232312,0.01572917,0.02182065,0.0005515777,0.06636371],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.03157628,"threshold_uncertainty_score":0.1669933,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052991207","doi":"10.1056/nejmoa012354","title":"Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Nelfinavir; Medicine; Virology; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV); Pharmacology; Viral load; Antiretroviral therapy","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Barry Bernstein","is_ca":false},{"name":"Martin King","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"Gildon Beall","is_ca":false},{"name":"Peter Ruane","is_ca":false},{"name":"Margaret Johnson","is_ca":false},{"name":"David W. Johnson","is_ca":false},{"name":"Richard Lalonde","is_ca":true},{"name":"Anthony J. Japour","is_ca":false},{"name":"Scott Brun","is_ca":false},{"name":"Eugene Sun","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08347689925760145,"gpt":0.3403015943720378,"spread":0.2568246951144364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106478,0.0006225025,0.001767513,0.0002678702,0.0003079318,0.0005366967,0.0005664833,0.000729038,0.004824531],"category_scores_gemma":[0.001676955,0.0002430893,0.0008713881,0.0001311265,0.0004677104,0.0004311198,0.0002288483,0.001712885,0.0004748692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005052694,"about_ca_system_score_gemma":0.0006449309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004971969,"about_ca_topic_score_gemma":0.001144414,"domain_scores_codex":[0.9996495,0.0001720036,0.00002951516,0.00005973849,0.00003340903,0.00005582835],"domain_scores_gemma":[0.999105,0.0003420047,0.000144568,0.00003264669,0.00003488813,0.0003408541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8724938,0.006249033,0.001658895,0.0007690751,0.0006006866,0.00007723337,0.000125416,0.0005975034,0.01011856,0.0001703808,0.0006894954,0.10645],"study_design_scores_gemma":[0.6416937,0.336533,0.01201063,0.0002411841,0.000832068,0.0002717773,0.00006352091,0.001540889,0.003968111,0.0002589544,0.002547563,0.00003862874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877332,0.008434557,0.0004335155,0.00051631,0.0002575387,0.0007604916,0.000162209,0.0000674348,0.001634845],"genre_scores_gemma":[0.994911,0.00193695,0.0007682531,0.0003969386,0.0002262879,0.0004514333,0.0001401003,0.000006383903,0.001162703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004824531,"threshold_uncertainty_score":0.01613963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009494891","doi":"10.1056/nejmoa1904398","title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Medicine; Confidence interval; Liter; Clinical endpoint; Internal medicine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Integrase inhibitor; Pharmacotherapy; Viral load; Randomized controlled trial; Antiretroviral therapy; Virology","authors":[{"name":"Susan Swindells","is_ca":false},{"name":"Jaime Andrade‐Villanueva","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Giuliano Rizzardini","is_ca":false},{"name":"Axel Baumgarten","is_ca":false},{"name":"Mar Masiá","is_ca":false},{"name":"Gulam Latiff","is_ca":false},{"name":"Vadim Pokrovsky","is_ca":false},{"name":"Fritz Bredeek","is_ca":false},{"name":"Graham Smith","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Kim Ys","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Christine L. Talarico","is_ca":false},{"name":"Parul Patel","is_ca":false},{"name":"Vasiliki Chounta","is_ca":false},{"name":"Herta Crauwels","is_ca":false},{"name":"Wim Parys","is_ca":false},{"name":"Simon Vanveggel","is_ca":false},{"name":"Joseph Mrus","is_ca":false},{"name":"Jenny Huang","is_ca":true},{"name":"Conn Harrington","is_ca":false},{"name":"Krischan J Hudson","is_ca":false},{"name":"David A. Margolis","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02603651210254818,"gpt":0.2850169726029176,"spread":0.2589804605003694,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001797132,0.0003779736,0.0007946501,0.0001989322,0.0001820327,0.0003553698,0.0005225876,0.0005096047,0.005049617],"category_scores_gemma":[0.001602471,0.0001567957,0.0005370984,0.0001846414,0.0004373059,0.0003775138,0.0002427635,0.00114172,0.0002515964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003571594,"about_ca_system_score_gemma":0.000638935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000415613,"about_ca_topic_score_gemma":0.001332208,"domain_scores_codex":[0.9993442,0.0003855525,0.00005176594,0.00007458419,0.00008820391,0.0000557135],"domain_scores_gemma":[0.9989154,0.000377728,0.0003517178,0.00006059998,0.00004041675,0.0002541762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7054235,0.01516087,0.01008062,0.002225096,0.001284314,0.0001101922,0.0001816158,0.001783588,0.0153316,0.0005069781,0.001375167,0.2465364],"study_design_scores_gemma":[0.6789767,0.274025,0.03568933,0.0002926262,0.0007944542,0.0004104382,0.00006703947,0.002594298,0.003419469,0.0005793027,0.003122384,0.0000289431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921721,0.00483615,0.0004600997,0.0002829847,0.00005770599,0.0007866197,0.0002288729,0.000022401,0.001153106],"genre_scores_gemma":[0.995915,0.001087595,0.001404111,0.0001968058,0.00007979165,0.0006712255,0.0001894709,0.000002951789,0.00045302],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005049617,"threshold_uncertainty_score":0.01689267,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162761942","doi":"10.1086/655681","title":"Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients","year":2010,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Renal function; Nephrotoxicity; Cochrane Library; Confidence interval; Meta-analysis; Internal medicine; Randomized controlled trial; Hypophosphatemia; Creatinine; Adverse effect; Relative risk; Kidney","authors":[{"name":"Ryan Cooper","is_ca":true},{"name":"Natasha Wiebe","is_ca":true},{"name":"Nathaniel Smith","is_ca":false},{"name":"Philip Keiser","is_ca":false},{"name":"Saraladevi Naicker","is_ca":false},{"name":"Marcello Tonelli","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04352254162317223,"gpt":0.3787250113462425,"spread":0.3352024697230703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0147069,0.002653557,0.02047892,0.005938485,0.0007371763,0.003436752,0.002193601,0.002424555,0.003815556],"category_scores_gemma":[0.03734041,0.00138066,0.03827468,0.007448013,0.0007267953,0.001755932,0.001359129,0.002401337,0.0002824113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002711094,"about_ca_system_score_gemma":0.00425391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008238248,"about_ca_topic_score_gemma":0.01467189,"domain_scores_codex":[0.9865482,0.007137196,0.003501817,0.001152855,0.001305542,0.0003542877],"domain_scores_gemma":[0.9771366,0.01685066,0.003620287,0.0006156139,0.001506882,0.0002700112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001677962,0.00002136497,0.00307718,0.3198654,0.6672745,0.0001156648,0.00004881288,0.0003920789,0.0001117583,0.00009141492,0.0004841341,0.006839689],"study_design_scores_gemma":[0.0006260874,0.0001824825,0.002767408,0.02189423,0.9729497,0.00008081241,0.000030053,0.000201731,0.00008212832,0.0001455305,0.001022119,0.0000177095],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004472306,0.9936805,0.0004334405,0.0002111268,0.0001965012,0.0002924151,0.0004322109,0.00002232379,0.0002591363],"genre_scores_gemma":[0.2167829,0.7761101,0.002583404,0.001220794,0.000394427,0.001526453,0.0009099811,0.00003408892,0.0004379048],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02047892,"threshold_uncertainty_score":0.0777784,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139430929","doi":"10.1016/s0140-6736(12)61853-4","title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada); Sunnybrook Health Science Centre; Health Sciences Centre","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Medicine; Emtricitabine; Integrase inhibitor; Abacavir; Lamivudine; Adverse effect; Clinical endpoint; Virology; Internal medicine; Efavirenz; Clinical trial; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","authors":[{"name":"François Raffi","is_ca":false},{"name":"Anita Rachlis","is_ca":true},{"name":"Hans‐Jürgen Stellbrink","is_ca":false},{"name":"W. D. Hardy","is_ca":false},{"name":"Carlo Torti","is_ca":false},{"name":"Chloe Orkin","is_ca":false},{"name":"Mark Bloch","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Vadim Pokrovsky","is_ca":false},{"name":"Federico Pulido","is_ca":false},{"name":"Steve Almond","is_ca":true},{"name":"David M. Margolis","is_ca":false},{"name":"Clare Brennan","is_ca":false},{"name":"Sherene Min","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03887473312597239,"gpt":0.28644908395491,"spread":0.2475743508289376,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003550972,0.002562833,0.006011304,0.0006290652,0.0004844852,0.001538078,0.001471468,0.003450915,0.01005417],"category_scores_gemma":[0.004398592,0.00153099,0.003897299,0.0004973749,0.001767398,0.002469696,0.0006901816,0.004069581,0.001982334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007896199,"about_ca_system_score_gemma":0.0007876899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001198281,"about_ca_topic_score_gemma":0.001935958,"domain_scores_codex":[0.9979469,0.001327154,0.0001361762,0.0002486016,0.0001147237,0.0002263917],"domain_scores_gemma":[0.9973074,0.001263735,0.0005177355,0.0003748191,0.0001131816,0.0004230751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9909145,0.001449599,0.0001252441,0.0004041995,0.0005836295,0.00001693842,0.00003223799,0.0001186484,0.000962418,0.0000407876,0.000239814,0.005112034],"study_design_scores_gemma":[0.9769542,0.02087272,0.001001766,0.00003297662,0.0004528239,0.00001474114,0.00002112646,0.0001638093,0.0001513957,0.0001382816,0.000178009,0.00001814742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985505,0.006675494,0.0009144419,0.000825538,0.0008975259,0.001370871,0.001485195,0.0001877282,0.002138168],"genre_scores_gemma":[0.9831518,0.003576009,0.001857041,0.00136889,0.000931605,0.001974195,0.0009321195,0.00007994818,0.006128416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01005417,"threshold_uncertainty_score":0.03363454,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021877795","doi":"10.1086/375597","title":"Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel","year":2003,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":516,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"U.S. Food and Drug Administration; International AIDS Society","keywords":"Medicine; Drug resistance; HIV drug resistance; Antiretroviral drug; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Antiretroviral therapy; Virology; Family medicine; Viral load; Biology","authors":[{"name":"Martin Hirsch","is_ca":false},{"name":"Françoise Brun‐Vézinet","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Brian Conway","is_ca":true},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Lisa M. Demeter","is_ca":false},{"name":"Scott M. Hammer","is_ca":false},{"name":"Victoria A. Johnson","is_ca":false},{"name":"Clive Loveday","is_ca":false},{"name":"John W. Mellors","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"Douglas D. Richman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04452468622132792,"gpt":0.3519511573071248,"spread":0.3074264710857969,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01982469,0.0009894822,0.001025953,0.003337408,0.00158634,0.001435894,0.003210855,0.005697811,0.001912275],"category_scores_gemma":[0.02258529,0.0007699574,0.001625564,0.00271321,0.0009600473,0.001314572,0.001535223,0.006672897,0.001338598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001519946,"about_ca_system_score_gemma":0.009607887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02155765,"about_ca_topic_score_gemma":0.03585234,"domain_scores_codex":[0.9915882,0.003257755,0.001917848,0.0002515213,0.002599939,0.0003846961],"domain_scores_gemma":[0.9666163,0.005808212,0.002607208,0.0005860369,0.02184574,0.002536668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000245402,0.0003940083,0.02348423,0.00192975,0.0001540496,0.0008746635,0.0006268321,0.0007631679,0.001862061,0.001325069,0.7152756,0.2530652],"study_design_scores_gemma":[0.0002345477,0.0003863712,0.05490604,0.008488153,0.0004912432,0.002111247,0.001134121,0.001750759,0.002691728,0.001942991,0.9257421,0.0001207324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.02327281,0.1369717,0.02714116,0.7006985,0.02178566,0.005108279,0.008289081,0.001060728,0.07567214],"genre_scores_gemma":[0.1466385,0.2396515,0.2451042,0.2848362,0.01388562,0.008421686,0.01720828,0.0004587913,0.04379521],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02155765,"threshold_uncertainty_score":0.1048443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2738541296","doi":"10.1016/s0140-6736(17)31917-7","title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada); Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Rilpivirine; Abacavir; Medicine; Lamivudine; Tolerability; Emtricitabine; Dosing; Internal medicine; Pharmacology; Adverse effect; Viral load; Virology; Human immunodeficiency virus (HIV)","authors":[{"name":"David A. Margolis","is_ca":false},{"name":"Juan González‐García","is_ca":false},{"name":"Hans-Jürgen Stellbrink","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Yazdan Yazdanpanah","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Thomas A. Lutz","is_ca":false},{"name":"Jonathan B. Angel","is_ca":true},{"name":"Gary Richmond","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Félix Gutiérrez","is_ca":false},{"name":"Louis Sloan","is_ca":false},{"name":"Marty St. Clair","is_ca":false},{"name":"Miranda Murray","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Joseph Mrus","is_ca":false},{"name":"Parul Patel","is_ca":false},{"name":"Herta Crauwels","is_ca":false},{"name":"Sandy Griffith","is_ca":false},{"name":"Kenneth Sutton","is_ca":false},{"name":"David Dorey","is_ca":true},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04306374395930505,"gpt":0.3384009476299573,"spread":0.2953372036706522,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003171953,0.002542546,0.003165114,0.0003866984,0.0004417706,0.001655017,0.001364005,0.003200469,0.01001342],"category_scores_gemma":[0.003042902,0.0009958873,0.002320762,0.0003871514,0.001562127,0.002584287,0.0006148518,0.004716399,0.002282665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008965912,"about_ca_system_score_gemma":0.0008365505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000902955,"about_ca_topic_score_gemma":0.001737752,"domain_scores_codex":[0.9988644,0.000670869,0.00005386562,0.0001622269,0.00006864851,0.0001800171],"domain_scores_gemma":[0.9982724,0.0005922218,0.0003355094,0.000203099,0.00008298207,0.0005138469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9802025,0.003619248,0.0003869238,0.0003167966,0.000535279,0.00004578636,0.00006435248,0.0002444396,0.002403051,0.00007596393,0.0007214578,0.01138434],"study_design_scores_gemma":[0.967898,0.02951932,0.00111652,0.00002828404,0.0002697064,0.00005042483,0.00002776423,0.0002239511,0.0002669412,0.0001313874,0.0004491184,0.00001852805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865638,0.005233278,0.0006855826,0.001145271,0.0004092255,0.001441192,0.001982201,0.0001837853,0.002355576],"genre_scores_gemma":[0.978314,0.003845639,0.002395426,0.001609906,0.0005692255,0.002942647,0.002722882,0.00009182023,0.007508475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01001342,"threshold_uncertainty_score":0.03349829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047734031","doi":"10.1086/427192","title":"Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Drug resistance; Internal medicine; Medicine; Hazard ratio; Viral load; Proportional hazards model; Cohort; Resistance mutation; Cohort study; Immunology; Virology; Human immunodeficiency virus (HIV); Reverse transcriptase; Confidence interval; Biology; Polymerase chain reaction; Genetics","authors":[{"name":"P. Richard Harrigan","is_ca":true},{"name":"Robert S. Hogg","is_ca":true},{"name":"Winnie Dong","is_ca":true},{"name":"Benita Yip","is_ca":true},{"name":"Brian Wynhoven","is_ca":true},{"name":"Justin Woodward","is_ca":true},{"name":"Chanson J. Brumme","is_ca":true},{"name":"Zabrina L. Brumme","is_ca":true},{"name":"Theresa Mo","is_ca":true},{"name":"Chris Alexander","is_ca":true},{"name":"Julio Montaner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007131593421158709,"gpt":0.2540523036130282,"spread":0.2469207101918695,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004397878,0.0002734181,0.0004390052,0.0005502543,0.0007289505,0.0008306582,0.0004426879,0.0004467265,0.001033973],"category_scores_gemma":[0.001854329,0.0003139252,0.0002612222,0.0007428915,0.0003079597,0.0002673367,0.0003013015,0.0006688821,0.0001894829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004992561,"about_ca_system_score_gemma":0.0008034797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07203328,"about_ca_topic_score_gemma":0.0775218,"domain_scores_codex":[0.9995949,0.00006446037,0.00002884147,0.0001082718,0.0001226405,0.00008095366],"domain_scores_gemma":[0.9988487,0.000217993,0.000388119,0.00008981003,0.0001647135,0.0002907069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005556184,0.00001902834,0.9991534,0.000002089311,0.00001656422,0.00005554532,0.0000401628,0.0000181242,0.0001785547,0.000003600684,0.00005303978,0.000404329],"study_design_scores_gemma":[0.000005193171,0.00003021154,0.9994261,0.000002540537,0.00001158203,0.0001627907,0.0001100704,0.0001553779,0.00002813392,0.000005160128,0.00006057872,0.000002322323],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996598,0.00006405513,0.00002008398,0.00001602671,0.000001838383,0.000004430396,0.0001449179,0.000001423284,0.00008747211],"genre_scores_gemma":[0.999567,0.00004946412,0.00002826865,0.0000130495,0.000003963911,0.000003893114,0.0002645951,0.000001107819,0.0000686448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07203328,"threshold_uncertainty_score":0.143228,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099826019","doi":"10.1016/s0140-6736(11)60936-7","title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"International AIDS Society","keywords":"Rilpivirine; Emtricitabine; Efavirenz; Medicine; Viral load; Internal medicine; Regimen; Reverse-transcriptase inhibitor; Virology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Jean‐Michel Molina","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Beatriz Grinsztejn","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Anthony Mills","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Khuanchai Supparatpinyo","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Herta Crauwels","is_ca":false},{"name":"L Rimsky","is_ca":false},{"name":"Simon Vanveggel","is_ca":false},{"name":"Katia Boven","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04770636682178646,"gpt":0.2973200934542903,"spread":0.2496137266325038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001872726,0.002423246,0.004603448,0.0005808098,0.0005370455,0.001393228,0.001334038,0.002654717,0.009320301],"category_scores_gemma":[0.002207282,0.001070924,0.002812275,0.000529948,0.001593926,0.001917578,0.0004873265,0.004197021,0.0013275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008404732,"about_ca_system_score_gemma":0.0009111558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001525223,"about_ca_topic_score_gemma":0.003391848,"domain_scores_codex":[0.9992884,0.0003427843,0.00004948935,0.0001427618,0.0000453864,0.0001312861],"domain_scores_gemma":[0.999037,0.000381564,0.0001829857,0.00007922297,0.00004746459,0.0002717697],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9903779,0.00176666,0.000109963,0.0004977767,0.0005188864,0.00002286793,0.00003193156,0.000115438,0.0008558814,0.00005668628,0.0002982032,0.005347744],"study_design_scores_gemma":[0.9841291,0.01481565,0.0003517579,0.00002053977,0.0002423659,0.00001203707,0.00001211552,0.000103023,0.00008290848,0.00005555574,0.0001667985,0.000008162213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978187,0.01020533,0.0008670268,0.001122734,0.001240171,0.003714491,0.001670343,0.0002406102,0.002752332],"genre_scores_gemma":[0.9765983,0.006417254,0.002143064,0.001678332,0.00087171,0.004851955,0.001148996,0.00004715917,0.006243076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009320301,"threshold_uncertainty_score":0.03117949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2032847961","doi":"10.1371/journal.pmed.0050158","title":"Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy","year":2008,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Public Health Agency of Canada","funders":"Centers for Disease Control and Prevention","keywords":"Drug resistance; Resistance mutation; HIV drug resistance; Genotyping; Drug; Virology; Reverse transcriptase; Genotype; Medicine; Viral load; Biology; Genetics; Virus; Pharmacology; Polymerase chain reaction; Antiretroviral therapy; Gene","authors":[{"name":"Jeffrey A. Johnson","is_ca":false},{"name":"LI Jin-fen","is_ca":false},{"name":"Xierong Wei","is_ca":false},{"name":"Jonathan Lipscomb","is_ca":false},{"name":"David M. Irlbeck","is_ca":false},{"name":"Charles Craig","is_ca":false},{"name":"Amanda Smith","is_ca":false},{"name":"Diane Bennett","is_ca":false},{"name":"Michael Monsour","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"E. Randall Lanier","is_ca":false},{"name":"Walid Heneine","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05074698755939865,"gpt":0.2885208412925289,"spread":0.2377738537331303,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005861002,0.0001943091,0.0002944868,0.0005319516,0.0004885049,0.0005244914,0.0002818747,0.0003858741,0.002142482],"category_scores_gemma":[0.002883353,0.0001957316,0.0001503535,0.0004240369,0.0004272627,0.0003077677,0.0001996423,0.0004532831,0.0001443892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003078989,"about_ca_system_score_gemma":0.0002713093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003289302,"about_ca_topic_score_gemma":0.00447556,"domain_scores_codex":[0.999567,0.0001024172,0.00003769943,0.00010703,0.0001211615,0.00006478675],"domain_scores_gemma":[0.9981292,0.0003700919,0.001072153,0.00009252654,0.0001543134,0.000181698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001462464,0.00005710222,0.9928716,0.00001618462,0.00004081659,0.0001783584,0.0001039943,0.0000355771,0.0016862,0.00004180773,0.0001075251,0.004714565],"study_design_scores_gemma":[0.000008169064,0.0001380374,0.9976133,0.000009584491,0.00003499107,0.001208021,0.000140446,0.0001935084,0.0003896319,0.00006628105,0.000194088,0.000003968551],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999117,0.0002536513,0.00008796152,0.00003616419,0.000002788994,0.000007477578,0.00004248218,0.00000397895,0.0004486288],"genre_scores_gemma":[0.9997266,0.00007139512,0.00007485648,0.00002344648,0.000006785262,0.000002934956,0.00003713465,0.000001161823,0.00005568647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003289302,"threshold_uncertainty_score":0.007167339,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990925084","doi":"10.1016/s1473-3099(13)70257-3","title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Dolutegravir; Medicine; Emtricitabine; Tolerability; Abacavir; Lamivudine; Population; Internal medicine; Clinical trial; Integrase inhibitor; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Antiretroviral therapy; Virology; Virus; Chronic hepatitis","authors":[{"name":"François Raffi","is_ca":false},{"name":"Hans Jaeger","is_ca":false},{"name":"Eugenia Quirós-Roldán","is_ca":false},{"name":"Helmut Albrecht","is_ca":false},{"name":"Elena Belonosova","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Jean-Guy Baril","is_ca":false},{"name":"Peré Domingo","is_ca":false},{"name":"Clare Brennan","is_ca":false},{"name":"Steve Almond","is_ca":true},{"name":"Sherene Min","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03039458746160299,"gpt":0.2889750520106316,"spread":0.2585804645490286,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003479032,0.003593256,0.005940785,0.0006638144,0.0006355709,0.00173063,0.001949254,0.003804122,0.01399705],"category_scores_gemma":[0.003848656,0.001596033,0.003912409,0.0005064805,0.002121557,0.002775961,0.0008293004,0.004816584,0.003040355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007903979,"about_ca_system_score_gemma":0.0008619599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001114439,"about_ca_topic_score_gemma":0.001845366,"domain_scores_codex":[0.9984401,0.0009329535,0.00009492526,0.0002727567,0.00008426329,0.0001750107],"domain_scores_gemma":[0.997749,0.0008446721,0.0004709049,0.0003453704,0.00009788258,0.000492105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.993193,0.001390956,0.0001015146,0.0003149868,0.0004128563,0.00001753022,0.00003100677,0.00009933424,0.0009849892,0.00004113909,0.0002556842,0.003157117],"study_design_scores_gemma":[0.9872722,0.01173515,0.0003509691,0.00001670556,0.0001937822,0.00001253125,0.0000112679,0.00009558179,0.00009975064,0.00007753015,0.0001236136,0.0000108342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822918,0.005825411,0.001173333,0.001180567,0.001242466,0.002866844,0.002615732,0.0003292774,0.002474675],"genre_scores_gemma":[0.971963,0.003989247,0.003418502,0.001810383,0.001333561,0.004768318,0.002028208,0.0001346764,0.01055421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01399705,"threshold_uncertainty_score":0.04682481,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164903312","doi":"10.1128/aac.45.10.2733-2739.2001","title":"Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults","year":2001,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Gilead Sciences (Canada)","funders":"National Institutes of Health; National Center for Research Resources; National Institute of Mental Health; Johns Hopkins University; University of Washington; Gilead Sciences","keywords":"Pharmacokinetics; Medicine; Placebo; Adverse effect; Dosing; Reverse-transcriptase inhibitor; Pharmacology; Discontinuation; Internal medicine; Virus; Gastroenterology; Sida; Virology; Viral disease; Pathology","authors":[{"name":"Patricia Barditch‐Crovo","is_ca":false},{"name":"Steven G. Deeks","is_ca":false},{"name":"Ann Collier","is_ca":false},{"name":"Sharon Safrin","is_ca":false},{"name":"Dion F. Coakley","is_ca":true},{"name":"Michael D. Miller","is_ca":true},{"name":"Brian P. Kearney","is_ca":true},{"name":"Rebecca Coleman","is_ca":true},{"name":"Patrick D. Lamy","is_ca":true},{"name":"James O. Kahn","is_ca":false},{"name":"Ian McGowan","is_ca":true},{"name":"Paul S. Lietman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01141155838644725,"gpt":0.2844821790997805,"spread":0.2730706207133333,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00113141,0.001789008,0.001756007,0.0003655097,0.0003970662,0.0007044194,0.0006444864,0.001550524,0.003883523],"category_scores_gemma":[0.001502182,0.000579096,0.0008627192,0.0003140305,0.001160288,0.0008129865,0.0002216561,0.002584878,0.0008040188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006363586,"about_ca_system_score_gemma":0.0008421274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007889772,"about_ca_topic_score_gemma":0.001399507,"domain_scores_codex":[0.9996326,0.0001741216,0.00002002856,0.00006235491,0.00003448738,0.00007648398],"domain_scores_gemma":[0.9992208,0.0001632882,0.0001440873,0.00006476351,0.00004314061,0.0003638797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9155777,0.02656326,0.001679454,0.0003338493,0.0004849309,0.0001234051,0.0001383789,0.0005788392,0.01382623,0.000235019,0.001845082,0.03861391],"study_design_scores_gemma":[0.8258169,0.1685664,0.002396677,0.00001650025,0.000160103,0.00007959461,0.00002170116,0.0004663676,0.001486859,0.0001595208,0.0008176893,0.00001167511],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907199,0.002595204,0.0006750476,0.0006633979,0.0002163991,0.002447769,0.0007728896,0.0001209164,0.001788423],"genre_scores_gemma":[0.9900832,0.001668111,0.001557063,0.000870854,0.0002122975,0.002009381,0.001184142,0.0000241129,0.002390786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003883523,"threshold_uncertainty_score":0.01299167,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106720283","doi":"10.1097/qad.0b013e328011e691","title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance","year":2006,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":331,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Reverse transcriptase; Drug resistance; HIV drug resistance; Virology; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Reverse-transcriptase inhibitor; Mutation; Protease inhibitor (pharmacology); Protease; Biology; Human immunodeficiency virus (HIV); Medicine; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy; Gene; Enzyme","authors":[{"name":"Robert W. Shafer","is_ca":false},{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"Veronica Miller","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Diane Bennett","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02809935969644671,"gpt":0.3117433572995661,"spread":0.2836439976031194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001536287,0.001396355,0.001732992,0.005422151,0.0003189447,0.0008725396,0.001361024,0.001258161,0.006429899],"category_scores_gemma":[0.002474753,0.0003138884,0.0008169121,0.003840779,0.0005524266,0.001596189,0.0005502441,0.001489291,0.006495752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008353927,"about_ca_system_score_gemma":0.001806358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001754107,"about_ca_topic_score_gemma":0.002425554,"domain_scores_codex":[0.9992802,0.0002134261,0.00009657462,0.00006908034,0.0003027633,0.00003796226],"domain_scores_gemma":[0.9989232,0.0004588981,0.0001529963,0.00005256961,0.0003626321,0.0000496836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000307842,0.00005755021,0.0002517819,0.01028262,0.00005515706,0.0001680138,0.00003277873,0.0002541167,0.0008892862,0.001973614,0.04130613,0.9446983],"study_design_scores_gemma":[0.00003029317,0.00006697384,0.001579423,0.008975605,0.0001376852,0.002109071,0.00005948437,0.0001930108,0.000716989,0.002330582,0.9837817,0.00001918223],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001018868,0.9957026,0.0006640286,0.0005477831,0.0003343151,0.00003087188,0.00004905164,0.00002648094,0.002543044],"genre_scores_gemma":[0.0008309626,0.9953003,0.002108907,0.0002852827,0.0001690462,0.00003702846,0.0001148068,0.000004926037,0.001148731],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006429899,"threshold_uncertainty_score":0.02151018,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W15969640","doi":"10.1177/135965350000500112","title":"The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan","year":2000,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Regimen; Internal medicine; Medicine; Drug resistance; Genotyping; Confounding; Viral load; HIV drug resistance; Observational study; Odds ratio; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology","authors":[{"name":"Victor DeGruttola","is_ca":false},{"name":"Lynn P. Dix","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Dan Holder","is_ca":false},{"name":"Andrew Phillips","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"John D. Baxter","is_ca":false},{"name":"Philippe Clevenbergh","is_ca":false},{"name":"Scott Hammer","is_ca":false},{"name":"Richard Harrigan","is_ca":true},{"name":"David Katzenstein","is_ca":false},{"name":"Randall Lanier","is_ca":false},{"name":"Michael D. Miller","is_ca":false},{"name":"Michael F. Para","is_ca":false},{"name":"Sabine Yerly","is_ca":false},{"name":"Andrew Zolopa","is_ca":false},{"name":"Jeffrey S. Murray","is_ca":false},{"name":"Amy K. Patick","is_ca":false},{"name":"Veronica Miller","is_ca":false},{"name":"Steven Castillo","is_ca":false},{"name":"Louise Pedneault","is_ca":false},{"name":"John W. Mellors","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05242918270470057,"gpt":0.345406405668464,"spread":0.2929772229637635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2361912,0.002327729,0.006826993,0.01528706,0.0007759409,0.005019018,0.002644212,0.001293214,0.0008913479],"category_scores_gemma":[0.2773544,0.001776263,0.01047636,0.01333963,0.001517641,0.002578173,0.002503869,0.001926252,0.0003786309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001621208,"about_ca_system_score_gemma":0.002692117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002829044,"about_ca_topic_score_gemma":0.002781955,"domain_scores_codex":[0.7320107,0.1506945,0.07729479,0.01301912,0.02500102,0.001979855],"domain_scores_gemma":[0.4650235,0.2653762,0.06838796,0.149914,0.050023,0.001275359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.01084347,0.0002313489,0.8263757,0.008326334,0.05995205,0.000562317,0.001281149,0.002919284,0.005551842,0.0009149212,0.001617703,0.08142387],"study_design_scores_gemma":[0.001571772,0.004466536,0.9049951,0.002493623,0.05077652,0.001557499,0.0009948638,0.004384874,0.009112387,0.0008434406,0.01847639,0.0003269239],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.798259,0.08856063,0.08772865,0.0008602018,0.0009057784,0.007537209,0.01117277,0.0005971647,0.004378693],"genre_scores_gemma":[0.9413899,0.006129299,0.03705412,0.0004590547,0.0003035628,0.004574378,0.009175304,0.0003044991,0.0006098486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2361912,"threshold_uncertainty_score":0.9419122,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133117185","doi":"10.1093/infdis/jiu051","title":"Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Medicine; Discontinuation; Regimen; Tolerability; Integrase inhibitor; Adverse effect; Viral load; Internal medicine; Population; Phases of clinical research; Pharmacology; Clinical trial; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Antonella Castagna","is_ca":false},{"name":"Franco Maggiolo","is_ca":false},{"name":"Giovanni Penco","is_ca":false},{"name":"David P. Wright","is_ca":false},{"name":"Anthony Mills","is_ca":false},{"name":"Robert Grossberg","is_ca":false},{"name":"Jean‐Michel Molina","is_ca":false},{"name":"Julie Chas","is_ca":false},{"name":"J. Durant","is_ca":false},{"name":"Santiago Moreno","is_ca":false},{"name":"Manuela Doroana","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"J. Huang","is_ca":true},{"name":"Sherene Min","is_ca":false},{"name":"Ivy Song","is_ca":false},{"name":"Cindy Vavro","is_ca":false},{"name":"Garrett Nichols","is_ca":false},{"name":"Jane Yeo","is_ca":false},{"name":"Judith A. Aberg","is_ca":false},{"name":"Bisher Akil","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"J.G. Baril","is_ca":false},{"name":"F. Blanco Quintana","is_ca":false},{"name":"Gary Blick","is_ca":false},{"name":"Vicente Boix Martínez","is_ca":false},{"name":"Olivier Bouchaud","is_ca":false},{"name":"Teresa Branco","is_ca":false},{"name":"U. Fritz Bredeek","is_ca":false},{"name":"MANUEL C. IGLESIAS","is_ca":false},{"name":"Nathan Clumeck","is_ca":false},{"name":"Brian Conway","is_ca":false},{"name":"E DeJesus","is_ca":false},{"name":"Jean L. Delassus","is_ca":false},{"name":"P. de Truchis","is_ca":false},{"name":"Giovanni Di Perri","is_ca":false},{"name":"Massimo Di Pietro","is_ca":false},{"name":"Joan Duggan","is_ca":false},{"name":"Claudine Duvivier","is_ca":false},{"name":"Richard Elion","is_ca":false},{"name":"Joseph Eron","is_ca":false},{"name":"Douglas N. Fish","is_ca":false},{"name":"Joseph Gathe","is_ca":false},{"name":"Richard Haubrich","is_ca":false},{"name":"Heather Henderson","is_ca":false},{"name":"Charles B. Hicks","is_ca":false},{"name":"Laurent Hocqueloux","is_ca":false},{"name":"Sally Hodder","is_ca":false},{"name":"CB Hsiao","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Michael J. Kozal","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Sujata N. Lalla-Reddy","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"F Leoncini","is_ca":false},{"name":"Josep M. Llibre","is_ca":false},{"name":"Kamal Mansinho","is_ca":false},{"name":"Philippe Morlat","is_ca":false},{"name":"Karam Mounzer","is_ca":false},{"name":"M. Murphy","is_ca":false},{"name":"C. Newman","is_ca":false},{"name":"Thuy Nguyen","is_ca":false},{"name":"Bacel Nseir","is_ca":false},{"name":"Patrick Philibert","is_ca":false},{"name":"Gilles Pialoux","is_ca":false},{"name":"Isabelle Poizot‐Martin","is_ca":false},{"name":"Moti Ramgopal","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Dominique Salmon Ceron","is_ca":false},{"name":"Paul E. Sax","is_ca":false},{"name":"A. Scarsella","is_ca":false},{"name":"Michael Sension","is_ca":false},{"name":"Peter Shalit","is_ca":false},{"name":"L Sighinolfi","is_ca":false},{"name":"Louis Sloan","is_ca":false},{"name":"Catherine B. Small","is_ca":false},{"name":"David Stein","is_ca":false},{"name":"K. Tashima","is_ca":false},{"name":"Pablo Tebas","is_ca":false},{"name":"Carlo Torti","is_ca":false},{"name":"Marc Tribble","is_ca":false},{"name":"Didier Troisvallets","is_ca":false},{"name":"Christos Tsoukas","is_ca":false},{"name":"Pompeyo Viciana Fernandez","is_ca":false},{"name":"Derek Ward","is_ca":false},{"name":"Darrell P. Wheeler","is_ca":false},{"name":"Timothy Wilkin","is_ca":false},{"name":"Guy-Patrick Yeni","is_ca":false},{"name":"J. Louise Martin-Carpenter","is_ca":false},{"name":"G. Uhlenbrauck","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008909296242199214,"gpt":0.2590626394812267,"spread":0.2501533432390275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002716881,0.0006355991,0.001200625,0.0001516822,0.0002413681,0.0009595718,0.0003576308,0.0007998176,0.0009682601],"category_scores_gemma":[0.001968984,0.0002398762,0.001162949,0.0002440687,0.0003141311,0.000428433,0.0002192961,0.001390056,0.0002927514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005219165,"about_ca_system_score_gemma":0.0006612555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008268401,"about_ca_topic_score_gemma":0.001457695,"domain_scores_codex":[0.9994522,0.0002721369,0.00004185886,0.00006974957,0.00008671101,0.00007741949],"domain_scores_gemma":[0.9987084,0.0003027176,0.0003129238,0.000106805,0.0001316039,0.0004377088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6086246,0.02454543,0.1287211,0.001169324,0.004189043,0.0003891129,0.0007428493,0.003568289,0.04565663,0.0002412626,0.005691173,0.1764613],"study_design_scores_gemma":[0.3051788,0.2904577,0.3834071,0.0001962401,0.002200502,0.0008978997,0.0002046292,0.004126358,0.006289971,0.0002546872,0.006674829,0.0001113047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945951,0.003139118,0.0002293594,0.000162206,0.00003506593,0.0003216242,0.0007395669,0.00002810016,0.0007497898],"genre_scores_gemma":[0.9961659,0.0007823291,0.000511136,0.0003690296,0.00004673126,0.00020544,0.001397432,0.00001369943,0.0005082047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002716881,"threshold_uncertainty_score":0.01436841,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2318022415","doi":"10.1056/nejm200103293441307","title":"Interactions among Drugs for HIV and Opportunistic Infections","year":2001,"lang":"en","type":"review","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Intensive care medicine; Opportunistic infection; Antiretroviral therapy; Antiretroviral drug; Immunology; Viral disease; Pharmacology; Viral load","authors":[{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"Keith Gallicano","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05834285616609883,"gpt":0.3637505953102433,"spread":0.3054077391441445,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005740552,0.001314963,0.001686699,0.002829522,0.0004356962,0.001079455,0.0008405902,0.001432042,0.00701612],"category_scores_gemma":[0.001133135,0.0002385367,0.0006273848,0.003381311,0.0004856819,0.001338708,0.0006292405,0.001270284,0.004962751],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005413871,"about_ca_system_score_gemma":0.0009537621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001302814,"about_ca_topic_score_gemma":0.003198715,"domain_scores_codex":[0.9994659,0.0001346418,0.00006659248,0.00005811635,0.0002380908,0.00003665709],"domain_scores_gemma":[0.9994055,0.000307528,0.0001251777,0.00001875479,0.0001018283,0.0000411422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005348347,0.00008597605,0.0002881893,0.01431187,0.0001297221,0.000443383,0.00006571569,0.0002221887,0.0007197444,0.001515845,0.05837294,0.9237909],"study_design_scores_gemma":[0.00002870656,0.0000785778,0.001441705,0.005410374,0.0001248368,0.004045574,0.00005516005,0.00005614128,0.0002398876,0.001205395,0.9873007,0.00001293701],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001135587,0.9965503,0.00008759786,0.0001822914,0.0002028647,0.0000095878,0.00001759042,0.000009831939,0.002826367],"genre_scores_gemma":[0.001014494,0.9963194,0.0002778473,0.0003913789,0.0002251952,0.0000130459,0.00003708741,0.000002127334,0.001719347],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00701612,"threshold_uncertainty_score":0.0234713,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144984387","doi":"10.1016/s0140-6736(06)69154-x","title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","year":2006,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"International AIDS Society","keywords":"Ritonavir; Regimen; Medicine; Protease inhibitor (pharmacology); Internal medicine; Viral load; Randomized controlled trial; Pharmacology; Gastroenterology; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Charles B. Hicks","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Christine Katlama","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Margaret Johnson","is_ca":false},{"name":"Dietmar Neubacher","is_ca":false},{"name":"Douglas L. Mayers","is_ca":false},{"name":"Hernan Valdez","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1782479061759761,"gpt":0.4109949463905229,"spread":0.2327470402145468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004525015,0.001264596,0.004176967,0.0005615986,0.0002777366,0.001270406,0.0007529965,0.001589928,0.003032866],"category_scores_gemma":[0.00394965,0.0007806568,0.002821219,0.0005608124,0.001131857,0.001636968,0.0005649676,0.002567989,0.0004210915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007142026,"about_ca_system_score_gemma":0.0007664399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005565096,"about_ca_topic_score_gemma":0.001705078,"domain_scores_codex":[0.9972025,0.001892117,0.0001965557,0.0003131942,0.0001435379,0.0002522293],"domain_scores_gemma":[0.9976616,0.001140341,0.0005042931,0.000236678,0.00007341267,0.0003837598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9655916,0.00172366,0.0009689478,0.0004902495,0.002266846,0.00002630484,0.0000492983,0.0005494306,0.002035494,0.00007911184,0.0001445827,0.02607459],"study_design_scores_gemma":[0.8425774,0.1439302,0.007805571,0.00009752168,0.003316466,0.00006476085,0.00003566955,0.0005873984,0.0007961883,0.0002274846,0.0005193783,0.00004199398],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897075,0.007730128,0.000430253,0.0003504777,0.0001597193,0.0003818776,0.0003563993,0.00005339681,0.0008302222],"genre_scores_gemma":[0.9959069,0.002103856,0.0008243906,0.000243248,0.0001413518,0.0002028846,0.0002967812,0.00001285463,0.0002675626],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004525015,"threshold_uncertainty_score":0.02393091,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2330399120","doi":"10.1097/00002030-200301030-00001","title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Biology; Virology; Efavirenz; Reverse transcriptase; Nevirapine; Genotype; Mutation; Genetics; Gene; Virus; Polymerase chain reaction; Viral load","authors":[{"name":"Bluma Brenner","is_ca":true},{"name":"Dan Turner","is_ca":false},{"name":"Maureen Oliveira","is_ca":false},{"name":"Daniela Moïsi","is_ca":false},{"name":"Mervi Detorio","is_ca":false},{"name":"Mauricio Carobene","is_ca":false},{"name":"Richard Marlink","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Michel Roger","is_ca":false},{"name":"Mark A. Wainberg","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0200485203743622,"gpt":0.2915979826713447,"spread":0.2715494622969825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001862788,0.0002026342,0.0001675348,0.0001987678,0.000197229,0.0002386868,0.0001425385,0.0003389591,0.001310501],"category_scores_gemma":[0.0004526797,0.00008996113,0.0001515586,0.0001604639,0.0001350909,0.0001044138,0.0001730654,0.000293126,0.0002270652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001508058,"about_ca_system_score_gemma":0.00007631403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005424509,"about_ca_topic_score_gemma":0.0003956063,"domain_scores_codex":[0.999731,0.00006226572,0.00003590577,0.00006590837,0.00005836875,0.00004648666],"domain_scores_gemma":[0.9997802,0.00006555991,0.00007326381,0.00002131808,0.00002496196,0.00003473831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0004646925,0.0001365658,0.04758305,0.00004284643,0.00002963527,0.0004862024,0.00009062496,0.0001442231,0.9457701,0.00005178972,0.0001037122,0.005096497],"study_design_scores_gemma":[0.00008494606,0.003027547,0.5821185,0.00007406534,0.00008698405,0.02001404,0.0003320857,0.002427665,0.3874358,0.0001496946,0.004222153,0.00002655354],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995059,0.0001253004,0.0001028339,0.00001062735,0.000002959071,0.00000456437,0.00004621837,0.00000331788,0.0001982518],"genre_scores_gemma":[0.9992798,0.00008604467,0.0002725905,0.00002594129,0.000004903522,0.000005008883,0.0001398276,0.000003242248,0.000182709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001310501,"threshold_uncertainty_score":0.004384041,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2097847166","doi":"10.1371/journal.pmed.0020112","title":"Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Doris Duke Charitable Foundation","keywords":"Reverse transcriptase; Virology; Drug resistance; Genotype; Biology; Lentivirus; Protease; Human immunodeficiency virus (HIV); Medicine; Genetics; Polymerase chain reaction; Viral disease; Gene; Enzyme","authors":[{"name":"Rami Kantor","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Brad Efron","is_ca":false},{"name":"A.P. Carvalho","is_ca":false},{"name":"Brian Wynhoven","is_ca":true},{"name":"Patricia Cane","is_ca":false},{"name":"John Clarke","is_ca":false},{"name":"Sunee Sirivichayakul","is_ca":false},{"name":"Marcelo A. Soares","is_ca":false},{"name":"Joke Snoeck","is_ca":false},{"name":"Candice Pillay","is_ca":false},{"name":"H Rudich","is_ca":false},{"name":"Rosângela Rodrigues","is_ca":false},{"name":"África Holguín","is_ca":false},{"name":"Koya Ariyoshi","is_ca":false},{"name":"María Belén Bouzas","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Wataru Sugiura","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Luís Fernando de Macedo Brígido","is_ca":false},{"name":"Zehava Grossman","is_ca":false},{"name":"Lynn Morris","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Amílcar Tanuri","is_ca":false},{"name":"Praphan Phanuphak","is_ca":false},{"name":"Jonathan Weber","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Ricardo Camacho","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01993683919710418,"gpt":0.294829505157253,"spread":0.2748926659601488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01524132,0.0007564833,0.0007063201,0.001109603,0.0003287973,0.001317754,0.0004912433,0.0004882737,0.001788599],"category_scores_gemma":[0.01132562,0.0001786227,0.001347408,0.003358945,0.0006342832,0.001469024,0.002399175,0.0006235897,0.000282061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006187567,"about_ca_system_score_gemma":0.001906742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008479324,"about_ca_topic_score_gemma":0.01079209,"domain_scores_codex":[0.9941621,0.003670184,0.0002459908,0.0008145953,0.0006851989,0.0004217678],"domain_scores_gemma":[0.984022,0.007595636,0.00299137,0.001785653,0.002236801,0.001368662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008361829,0.00009900392,0.9335446,0.0004973254,0.001484853,0.000188876,0.001337387,0.001911805,0.0003658807,0.0004932985,0.002888806,0.05635199],"study_design_scores_gemma":[0.00004769602,0.0004148661,0.9885212,0.000318777,0.00103582,0.0002942618,0.001934261,0.0008185079,0.0002533308,0.0002727895,0.006065473,0.00002293693],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9640703,0.01485888,0.002230277,0.002456311,0.00008043669,0.00008667472,0.008485279,0.00007088859,0.007660851],"genre_scores_gemma":[0.9874108,0.004549025,0.00162581,0.0005325055,0.00006936934,0.0000390507,0.005060506,0.0000593644,0.0006535003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01524132,"threshold_uncertainty_score":0.08060479,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2040027667","doi":"10.1097/qai.0b013e31819675e9","title":"The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; University of British Columbia; St. Paul's Hospital","funders":"National Institute of Mental Health; University of British Columbia","keywords":"Efavirenz; Lopinavir; Atazanavir; Hazard ratio; Medicine; Internal medicine; Nevirapine; Ritonavir; Reverse-transcriptase inhibitor; Confidence interval; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","authors":[{"name":"Viviane D. Lima","is_ca":true},{"name":"Richard Harrigan","is_ca":true},{"name":"David R. Bangsberg","is_ca":false},{"name":"Robert S. Hogg","is_ca":true},{"name":"Robert Gross","is_ca":false},{"name":"Benita Yip","is_ca":true},{"name":"Julio Montaner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01268521441145212,"gpt":0.2776353931414786,"spread":0.2649501787300265,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004266585,0.000316455,0.0004027522,0.0004235259,0.0002997666,0.0006622381,0.0003912609,0.0007141329,0.001511704],"category_scores_gemma":[0.01253705,0.0002284858,0.001052069,0.0006521894,0.0002614991,0.0006951235,0.0007471172,0.001020724,0.0001500045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002981045,"about_ca_system_score_gemma":0.0004105571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002109949,"about_ca_topic_score_gemma":0.002412387,"domain_scores_codex":[0.9977109,0.001212459,0.0002006219,0.0002747974,0.0003766337,0.0002245181],"domain_scores_gemma":[0.9880078,0.004542341,0.005053083,0.001030018,0.0005175,0.0008492352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00046655,0.00007523142,0.9942347,0.00001600009,0.0003095173,0.00003210109,0.00004209356,0.0002548014,0.0001313584,0.00002824826,0.00005025544,0.004359096],"study_design_scores_gemma":[0.000005674075,0.0002583688,0.9980633,0.00000977705,0.00009018967,0.0001001002,0.00003577596,0.001248112,0.00005291041,0.00006018261,0.00007229493,0.000003316334],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977728,0.001155899,0.0003082925,0.0002258991,0.00001032243,0.00000681196,0.0002093855,0.000006530712,0.0003041759],"genre_scores_gemma":[0.9994026,0.0001425233,0.0001338668,0.00002837999,0.00001932083,0.000005656101,0.0001326599,0.00000140875,0.0001335701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004266585,"threshold_uncertainty_score":0.02256417,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2014005798","doi":"10.1097/01.aids.0000199825.34241.49","title":"Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":316,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service","keywords":"Drug resistance; Nelfinavir; HIV drug resistance; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Drug; Biology; Protease inhibitor (pharmacology); Population; Nevirapine; Medicine; Internal medicine; Virus; Viral disease; Pharmacology; Sida; Viral load; Polymerase chain reaction; Antiretroviral therapy; Genetics","authors":[{"name":"David R. Bangsberg","is_ca":false},{"name":"Edward P. Acosta","is_ca":false},{"name":"Reena Gupta","is_ca":false},{"name":"David Guzman","is_ca":false},{"name":"Elise D. Riley","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Neil Parkin","is_ca":false},{"name":"Steven G. Deeks","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01743706402851803,"gpt":0.2396594699764665,"spread":0.2222224059479485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001975401,0.0004368846,0.0004479817,0.001181815,0.0003599989,0.0006846775,0.0005037947,0.0008718831,0.00460859],"category_scores_gemma":[0.01305874,0.0002881904,0.001043263,0.000634816,0.0004350898,0.000732679,0.0009422021,0.001150843,0.000438654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001643907,"about_ca_system_score_gemma":0.0002078867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001469449,"about_ca_topic_score_gemma":0.0006552887,"domain_scores_codex":[0.9978771,0.0009824986,0.0001778221,0.0004040931,0.0002744037,0.0002840299],"domain_scores_gemma":[0.9919422,0.003603535,0.00282095,0.0007030827,0.0003461264,0.0005841097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003416579,0.000043852,0.9966038,0.000009338821,0.0001991574,0.0000769609,0.00008443727,0.0001306609,0.000345051,0.00006439621,0.00004472953,0.002055912],"study_design_scores_gemma":[0.00002236331,0.0003541317,0.9957574,0.00001352426,0.0001032888,0.0006657938,0.0001560653,0.002581064,0.00008026583,0.0001851851,0.00007419285,0.000006659855],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986726,0.0003302287,0.0003302502,0.0001097254,0.00000621923,0.000009101226,0.00007639508,0.000007948966,0.0004575034],"genre_scores_gemma":[0.9997451,0.00002897741,0.00007621734,0.00001153053,0.00001017208,0.000004293643,0.00005710021,0.000002591368,0.00006401791],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00460859,"threshold_uncertainty_score":0.01541728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2172274075","doi":"10.1086/431199","title":"Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published Literature","year":2005,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Viral load; Observational study; Meta-analysis; MEDLINE; Antiretroviral therapy; Internal medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Family medicine","authors":[{"name":"Louise C. Ivers","is_ca":false},{"name":"David C. Kendrick","is_ca":false},{"name":"Karen Doucette","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1037390807758232,"gpt":0.4067970990395495,"spread":0.3030580182637263,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02808147,0.003721567,0.02133799,0.007933152,0.0008406294,0.004827155,0.002920092,0.002843609,0.003646318],"category_scores_gemma":[0.05474645,0.002008856,0.05943819,0.009472514,0.000822471,0.002076645,0.001922936,0.002622788,0.0004103555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0026549,"about_ca_system_score_gemma":0.002715759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005274349,"about_ca_topic_score_gemma":0.007672236,"domain_scores_codex":[0.9774559,0.0133636,0.004926916,0.0018818,0.001796371,0.0005755157],"domain_scores_gemma":[0.9469023,0.04145632,0.00695564,0.001776982,0.002367966,0.0005408229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00191036,0.00002054024,0.004099727,0.06031599,0.9303555,0.000101416,0.00003677509,0.0004102756,0.0000772941,0.00004153096,0.0001817632,0.002448768],"study_design_scores_gemma":[0.0004057449,0.0001554222,0.002824374,0.004711328,0.991168,0.00006090757,0.00002666095,0.0001500191,0.00005460469,0.00008585872,0.0003441663,0.00001290972],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01811965,0.9787276,0.001067731,0.0003096172,0.0002871087,0.0003441818,0.0006819502,0.00005424969,0.0004078364],"genre_scores_gemma":[0.4999931,0.4917402,0.003343577,0.001127426,0.0004781933,0.001418898,0.001384779,0.00008725264,0.0004266078],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02808147,"threshold_uncertainty_score":0.1485108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120293408","doi":"10.1016/s1473-3099(09)70328-7","title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Resistance mutation; Lamivudine; Drug resistance; Regimen; Medicine; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Genotyping; Internal medicine; Antiretroviral therapy; Etravirine; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Biology; Genotype; Virus; Polymerase chain reaction; Genetics","authors":[{"name":"Roos E. Barth","is_ca":false},{"name":"Maarten F. Schim van der Loeff","is_ca":true},{"name":"Rob Schuurman","is_ca":false},{"name":"Andy I. M. Hoepelman","is_ca":false},{"name":"Annemarie M. J. Wensing","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0288175057813383,"gpt":0.3038787431304422,"spread":0.2750612373491039,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004256535,0.000910947,0.007444905,0.002839395,0.0003974841,0.001357944,0.001563085,0.001430791,0.002431501],"category_scores_gemma":[0.02385691,0.0008474879,0.007601199,0.004740736,0.0005315006,0.001475882,0.001039347,0.00121598,0.0001191277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001641652,"about_ca_system_score_gemma":0.004072916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01227349,"about_ca_topic_score_gemma":0.03324331,"domain_scores_codex":[0.9962721,0.001330064,0.001333681,0.0004133293,0.0005089383,0.000141884],"domain_scores_gemma":[0.9850783,0.01088571,0.002852853,0.0001965539,0.0007055956,0.0002809424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.001758501,0.00006982332,0.0123339,0.855943,0.04827707,0.0002374182,0.0004965967,0.0002278569,0.0001818735,0.0001056456,0.001673067,0.07869526],"study_design_scores_gemma":[0.002368355,0.001425791,0.073085,0.5590324,0.3481717,0.001020355,0.001028765,0.0002588652,0.0003237386,0.0003068961,0.01285516,0.0001230136],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005212702,0.9940082,0.00006171871,0.00008628163,0.00008054291,0.0001045741,0.0003225178,0.000004129966,0.0001192368],"genre_scores_gemma":[0.1165331,0.8816912,0.000600891,0.0004297984,0.00009456899,0.0002225802,0.0003317907,0.00000435798,0.00009171161],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01227349,"threshold_uncertainty_score":0.02440411,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122026430","doi":"10.1093/infdis/jis750","title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","year":2012,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Dolutegravir; Raltegravir; Regimen; Cohort; Medicine; Viral load; Integrase inhibitor; Elvitegravir; Dosing; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Joseph J. Eron","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"J. Durant","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Isabelle Poizot‐Martin","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"Tamio Fujiwara","is_ca":false},{"name":"Jenny Huang","is_ca":true},{"name":"Sherene Min","is_ca":false},{"name":"Cindy Vavro","is_ca":false},{"name":"Jane Yeo","is_ca":false},{"name":"Sharon Walmsley","is_ca":false},{"name":"Joseph Cox","is_ca":false},{"name":"Jacques Reynes","is_ca":false},{"name":"Philippe Morlat","is_ca":false},{"name":"Daniel Vittecoq","is_ca":false},{"name":"Jean‐Michel Livrozet","is_ca":false},{"name":"Pompeyo Viciana Fernández","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Edwin DeJesus","is_ca":false},{"name":"Jerome DeVente","is_ca":false},{"name":"Jacob Lalezari","is_ca":false},{"name":"Lewis McCurdy","is_ca":false},{"name":"Louis A. Sloan","is_ca":false},{"name":"Benjamin Young","is_ca":false},{"name":"Anthony LaMarca","is_ca":false},{"name":"Trevor Hawkins","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01656090380541293,"gpt":0.27322790795775,"spread":0.2566670041523371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002582891,0.0006242403,0.00140123,0.0002464184,0.0002711701,0.0009687302,0.0003780255,0.0008088351,0.001267545],"category_scores_gemma":[0.002341529,0.0002978014,0.0009961971,0.000270201,0.0004142066,0.0004857495,0.0002919746,0.001127701,0.0004262381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000558784,"about_ca_system_score_gemma":0.0005588894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009826102,"about_ca_topic_score_gemma":0.001081422,"domain_scores_codex":[0.9992292,0.0003967733,0.00004453257,0.0001035911,0.0001148866,0.0001110319],"domain_scores_gemma":[0.998737,0.0002411663,0.0004003059,0.0001459801,0.0001394441,0.0003361116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4827934,0.0132271,0.3009402,0.0006822012,0.004337766,0.000396637,0.001203847,0.002140493,0.0396325,0.0001395637,0.002327489,0.152179],"study_design_scores_gemma":[0.08521339,0.2013309,0.6972971,0.00008153891,0.002157954,0.0006881706,0.0002214273,0.00224172,0.005307334,0.0001693815,0.005172986,0.0001180772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980008,0.0008303575,0.00009483139,0.00005334978,0.00001063637,0.0001237802,0.0003328776,0.00001301056,0.0005403343],"genre_scores_gemma":[0.9985104,0.0002453461,0.0001237242,0.00009084077,0.00002199595,0.00006376968,0.0005203432,0.000006465457,0.0004171265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002582891,"threshold_uncertainty_score":0.01365983,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112519486","doi":"10.1182/blood-2009-02-205153","title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Hamilton Health Sciences; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Ribavirin; Myeloid leukemia; Cancer research; Leukemia; Medicine; Myeloid; Clinical trial; Acute leukemia; Initiation factor; Translation (biology); Biology; Oncology; Immunology; Internal medicine; Messenger RNA; Gene; Genetics; Virus","authors":[{"name":"Sarit Assouline","is_ca":true},{"name":"Biljana Čuljković","is_ca":true},{"name":"Eftihia Cocolakis","is_ca":true},{"name":"Caroline Rousseau","is_ca":true},{"name":"Nathalie Beslu","is_ca":true},{"name":"Abdellatif Amri","is_ca":true},{"name":"Stephen Caplan","is_ca":true},{"name":"Brian Leber","is_ca":true},{"name":"Denis‐Claude Roy","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Katherine L. B. Borden","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01867370532849957,"gpt":0.3086300032636587,"spread":0.2899562979351591,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246212,0.0006910454,0.0009635703,0.0003158432,0.0002368081,0.0005515868,0.0005314157,0.001086737,0.002359202],"category_scores_gemma":[0.0006205944,0.0002483449,0.0005893723,0.0002125511,0.0005987002,0.0005413074,0.000303679,0.001760759,0.0003194998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000351697,"about_ca_system_score_gemma":0.0004927062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003179601,"about_ca_topic_score_gemma":0.0007228691,"domain_scores_codex":[0.9997731,0.0001232561,0.00001288507,0.00002237839,0.00002581755,0.00004251402],"domain_scores_gemma":[0.9997795,0.00006661643,0.00004976504,0.00001785408,0.00001299038,0.00007315777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4409589,0.05103676,0.002330913,0.002102781,0.0008070472,0.0004701157,0.0002960162,0.003566176,0.1039322,0.002107649,0.004463855,0.3879276],"study_design_scores_gemma":[0.4317023,0.5306457,0.006494848,0.0001481404,0.0003354206,0.0005682357,0.00007876035,0.001819022,0.01773232,0.0005969018,0.009849312,0.00002906356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834523,0.007610002,0.00165913,0.0009921977,0.0002343227,0.002904831,0.0006907539,0.0001468392,0.002309524],"genre_scores_gemma":[0.9871795,0.005056411,0.002968791,0.000647154,0.0001753066,0.001631776,0.0006530764,0.00001657552,0.001671377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002359202,"threshold_uncertainty_score":0.00789237,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2196190612","doi":"10.1016/s1473-3099(15)00348-5","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":304,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Tenofovir alafenamide; Medicine; Emtricitabine; Cobicistat; Regimen; Tolerability; Internal medicine; Rilpivirine; Clinical endpoint; Elvitegravir; Pharmacology; Viral load; Adverse effect; Gastroenterology; Clinical trial; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","authors":[{"name":"Anthony Mills","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"Jaime Andrade‐Villanueva","is_ca":false},{"name":"Giovanni DiPerri","is_ca":false},{"name":"Jan van Lunzen","is_ca":false},{"name":"Ellen Koenig","is_ca":false},{"name":"Richard Elion","is_ca":false},{"name":"Matthias Cavassini","is_ca":false},{"name":"José Valdez Madruga","is_ca":false},{"name":"Jason Brunetta","is_ca":true},{"name":"David Shamblaw","is_ca":false},{"name":"Edwin DeJesus","is_ca":false},{"name":"Chloe Orkin","is_ca":false},{"name":"David A. Wohl","is_ca":false},{"name":"Indira Brar","is_ca":false},{"name":"Jeffrey L. Stephens","is_ca":false},{"name":"Pierre-Marie Girard","is_ca":false},{"name":"Gregory Huhn","is_ca":false},{"name":"Andrew Plummer","is_ca":false},{"name":"Ya-Pei Liu","is_ca":false},{"name":"Andrew Cheng","is_ca":false},{"name":"Scott McCallister","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03418472364530394,"gpt":0.3281702941383671,"spread":0.2939855704930631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001630906,0.001437154,0.002725143,0.0003982309,0.000381821,0.001086785,0.0007989891,0.001734314,0.004494305],"category_scores_gemma":[0.002092113,0.0005972118,0.001903047,0.0004000726,0.001218962,0.001310976,0.0003310766,0.002757887,0.0005722768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006668122,"about_ca_system_score_gemma":0.0007729502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001219768,"about_ca_topic_score_gemma":0.00223065,"domain_scores_codex":[0.9991361,0.0004227948,0.00006246622,0.0001412433,0.00007048374,0.0001669747],"domain_scores_gemma":[0.9988532,0.0004591684,0.0002012857,0.00009885633,0.00005479154,0.0003327602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9706711,0.008917865,0.0006276693,0.000412877,0.0008143225,0.0000376592,0.0001007747,0.0002570912,0.002760128,0.00006614169,0.0002586802,0.01507565],"study_design_scores_gemma":[0.8995351,0.09649746,0.002547064,0.00002672433,0.0003776079,0.00002687832,0.00004044473,0.0002676882,0.0003209911,0.0001112066,0.0002323942,0.00001658674],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961798,0.001491674,0.000292583,0.0001761887,0.000205676,0.0007670593,0.0002632267,0.00003386855,0.0005900157],"genre_scores_gemma":[0.9956696,0.001045921,0.0006938193,0.0004556896,0.0002222848,0.0007571836,0.0002850102,0.00001268447,0.0008578534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004494305,"threshold_uncertainty_score":0.01503497,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129710521","doi":"10.1001/jama.285.9.1155","title":"Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>","year":2001,"lang":"id","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":279,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lamivudine; Indinavir; Abacavir; Zidovudine; Medicine; Regimen; Virology; Placebo; Efavirenz; Internal medicine; Stavudine; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy","authors":[{"name":"Schlomo Staszewski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01464476412462442,"gpt":0.2650518327198785,"spread":0.2504070685952541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002084269,0.001547219,0.003178592,0.0004050498,0.0005887875,0.001055623,0.0009009083,0.001808827,0.006147171],"category_scores_gemma":[0.002188469,0.0008465959,0.002049524,0.000367977,0.001204436,0.00108287,0.0004506553,0.002814759,0.0008239716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007398518,"about_ca_system_score_gemma":0.001170512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001058299,"about_ca_topic_score_gemma":0.002067953,"domain_scores_codex":[0.9988585,0.0006609253,0.0001010207,0.0001432267,0.0000699244,0.0001665174],"domain_scores_gemma":[0.9983324,0.0004413671,0.0004287861,0.00009451118,0.0001103955,0.0005924741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9887835,0.004517548,0.000631196,0.0001991801,0.0003724934,0.00001609329,0.00002764457,0.00008909193,0.00100447,0.00003459265,0.0001880281,0.004136127],"study_design_scores_gemma":[0.9131234,0.08412547,0.001692572,0.00001847268,0.0003437357,0.00001565813,0.00001579384,0.0002003691,0.0002255189,0.0000614183,0.0001709073,0.000006677905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922926,0.001991417,0.0003032765,0.0003619049,0.0003774282,0.003216469,0.0004842173,0.00004896801,0.0009236137],"genre_scores_gemma":[0.9928281,0.0009559663,0.0007032631,0.0007116201,0.0004443024,0.002723671,0.0004115867,0.000007806939,0.001213637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006147171,"threshold_uncertainty_score":0.02056438,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3000709627","doi":"10.1093/cid/ciz1243","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","year":2020,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Medicine; Dolutegravir; Regimen; Lamivudine; Adverse effect; Internal medicine; Population; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Virus; Hepatitis B virus","authors":[{"name":"Jean van Wyk","is_ca":false},{"name":"Faïza Ajana","is_ca":false},{"name":"Fiona Bisshop","is_ca":false},{"name":"Stéphane De Wit","is_ca":false},{"name":"Olayemi Osiyemi","is_ca":false},{"name":"Joaquín Portilla","is_ca":false},{"name":"Jean‐Pierre Routy","is_ca":true},{"name":"Christoph Wyen","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"Maria Cláudia Nascimento","is_ca":false},{"name":"Keith A. Pappa","is_ca":false},{"name":"Ruolan Wang","is_ca":false},{"name":"Jonathan Wright","is_ca":false},{"name":"Allan R. Tenorio","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Michael Aboud","is_ca":false},{"name":"Martin Gartland","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02162887313150714,"gpt":0.3442438337001976,"spread":0.3226149605686905,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001675767,0.001064279,0.001250427,0.0002592131,0.0003352245,0.0008318314,0.0006109934,0.0009987635,0.003470584],"category_scores_gemma":[0.001709275,0.0003849425,0.001873213,0.0002416856,0.0008293723,0.0007750327,0.0003610419,0.001679449,0.0003542218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001049177,"about_ca_system_score_gemma":0.001189634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001608174,"about_ca_topic_score_gemma":0.003334848,"domain_scores_codex":[0.9992774,0.0003844653,0.0000522882,0.0001236769,0.0000663387,0.00009580408],"domain_scores_gemma":[0.9987125,0.0002914358,0.0004182173,0.00008841632,0.00005882605,0.0004305259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9600388,0.009579946,0.007219233,0.0003730406,0.001121664,0.00006645562,0.0001284593,0.0003656367,0.003598357,0.00006658839,0.0007662352,0.01667546],"study_design_scores_gemma":[0.7760012,0.1923352,0.02720771,0.00007712776,0.001460973,0.0001306653,0.00007063057,0.000851147,0.0009468101,0.0002060211,0.0006744927,0.00003804783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969475,0.0009498515,0.0001172686,0.0001420774,0.0000492057,0.0005827695,0.0005481218,0.00001628313,0.0006469652],"genre_scores_gemma":[0.9967002,0.0004695798,0.0004125258,0.0003557253,0.00008526203,0.0007415722,0.0006904443,0.000007681505,0.0005369199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003470584,"threshold_uncertainty_score":0.01161021,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3196876339","doi":"10.1177/135965350801302s03","title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Developing country; Public health; Resource (disambiguation); Human immunodeficiency virus (HIV); Environmental health; Antiretroviral therapy; Economic growth; Viral load; Family medicine; Nursing; Surgery; Computer science","authors":[{"name":"Diane Bennett","is_ca":false},{"name":"Silvia Bertagnolio","is_ca":false},{"name":"Donald Sutherland","is_ca":true},{"name":"Charles F. Gilks","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02974505837060322,"gpt":0.3470594945262849,"spread":0.3173144361556817,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009834053,0.003641983,0.002619193,0.004514265,0.0006509061,0.002802897,0.00316584,0.002706203,0.01416073],"category_scores_gemma":[0.007829631,0.0007390635,0.001250566,0.004885922,0.001078329,0.001639941,0.0025078,0.004084183,0.008568119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002334451,"about_ca_system_score_gemma":0.0201874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02276331,"about_ca_topic_score_gemma":0.01207717,"domain_scores_codex":[0.9946076,0.002750976,0.0004287114,0.000164055,0.001679375,0.0003692605],"domain_scores_gemma":[0.9909657,0.001245856,0.001186682,0.0003819964,0.005210381,0.001009464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000145291,0.000215232,0.003018986,0.002915901,0.0001286905,0.0001621254,0.0001834774,0.0004145529,0.0007004626,0.003115083,0.7510426,0.2379577],"study_design_scores_gemma":[0.0001453381,0.0002292951,0.01400091,0.00386651,0.0001178793,0.0002285393,0.0002373124,0.0004002851,0.0005055143,0.001292258,0.9789336,0.00004252108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.009542534,0.2543572,0.03087008,0.1815054,0.03778197,0.02343052,0.1587922,0.004104008,0.2996162],"genre_scores_gemma":[0.03991521,0.3762227,0.145177,0.06804305,0.009172802,0.01657273,0.1545487,0.0010021,0.1893457],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.02276331,"threshold_uncertainty_score":0.05200803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045871034","doi":"10.1016/s1473-3099(09)70136-7","title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","year":2009,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"Seventh Framework Programme","keywords":"Lamivudine; Reverse transcriptase; Medicine; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Nucleoside analogue; Didanosine; Virology; Nucleoside; Viral load; Zidovudine; Resistance mutation; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease; Biology; Virus; RNA","authors":[{"name":"Ravindra K. Gupta","is_ca":false},{"name":"Andrew Hill","is_ca":false},{"name":"Anthony Sawyer","is_ca":false},{"name":"Alessandro Cozzi‐Lepri","is_ca":false},{"name":"Viktor von Wyl","is_ca":false},{"name":"Sabine Yerly","is_ca":false},{"name":"Viviane D. Lima","is_ca":true},{"name":"Huldrych F. Günthard","is_ca":false},{"name":"Charles F. Gilks","is_ca":false},{"name":"Deenan Pillay","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07017780613493417,"gpt":0.3493240932979655,"spread":0.2791462871630313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009086234,0.002051749,0.01556884,0.003353452,0.0004339878,0.001849691,0.001784506,0.002088747,0.002530189],"category_scores_gemma":[0.02665374,0.001551129,0.02743917,0.004555415,0.0005610487,0.001299727,0.001114575,0.001769158,0.000197198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001998185,"about_ca_system_score_gemma":0.002325278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007707738,"about_ca_topic_score_gemma":0.02242207,"domain_scores_codex":[0.9928597,0.003431394,0.001848029,0.0008060648,0.0008470971,0.0002077717],"domain_scores_gemma":[0.9822875,0.01260908,0.003424498,0.0005168423,0.0009233805,0.0002385999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.003665576,0.00004800588,0.007859003,0.1919686,0.7763486,0.0001191967,0.0001096984,0.0004408316,0.000194207,0.00007372307,0.0006445334,0.01852804],"study_design_scores_gemma":[0.001031782,0.0002884849,0.005267365,0.01007093,0.9819942,0.00009485119,0.00004328893,0.0001470413,0.00008732553,0.00008161508,0.0008704471,0.00002254321],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.009308153,0.9893757,0.0003708247,0.0001147002,0.0001787024,0.000134327,0.0003362954,0.00002030554,0.0001609088],"genre_scores_gemma":[0.3446274,0.6500837,0.002733644,0.0008988636,0.0002846,0.0004927971,0.0005085702,0.00002879116,0.0003417328],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01556884,"threshold_uncertainty_score":0.04805321,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157533742","doi":"10.1086/497610","title":"Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; ACT Government; School of Medicine, Vanderbilt University; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases","keywords":"Efavirenz; Nelfinavir; CYP2B6; CYP2C19; Medicine; Population; Pharmacology; Pharmacogenetics; Abacavir; Internal medicine; Virology; Biology; Viral load; Genotype; Virus; CYP3A4; Genetics; Cytochrome P450; Antiretroviral therapy","authors":[{"name":"David W. Haas","is_ca":false},{"name":"Laura Smeaton","is_ca":false},{"name":"Robert W. Shafer","is_ca":false},{"name":"Gregory K. Robbins","is_ca":false},{"name":"Gene D. Morse","is_ca":false},{"name":"Line Labbé","is_ca":true},{"name":"G. Wilkinson","is_ca":false},{"name":"David B. Clifford","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Victor De Gruttola","is_ca":false},{"name":"Richard B. Pollard","is_ca":false},{"name":"Thomas C. Merigan","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"Alfred L. George","is_ca":false},{"name":"John P. Donahue","is_ca":false},{"name":"Richard B. Kim","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07383009193538165,"gpt":0.4336922300749886,"spread":0.359862138139607,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077763,0.0007999258,0.00124016,0.0002885652,0.0003921956,0.0007348155,0.0006608809,0.001144441,0.001990444],"category_scores_gemma":[0.007471633,0.0004053168,0.00119342,0.0007949386,0.0004734096,0.000513515,0.0003394853,0.0009198266,0.0003291718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003463996,"about_ca_system_score_gemma":0.0005512037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004715424,"about_ca_topic_score_gemma":0.0007260782,"domain_scores_codex":[0.9948607,0.003903794,0.0003328816,0.0004977867,0.0002571681,0.0001476234],"domain_scores_gemma":[0.9935163,0.002410708,0.002206419,0.0009194742,0.0003987726,0.0005481955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3831321,0.003705145,0.5593317,0.0005773049,0.01803348,0.0003974159,0.0002714599,0.001585063,0.004735823,0.000257048,0.001329038,0.0266445],"study_design_scores_gemma":[0.1059559,0.05097384,0.8241321,0.0001402348,0.01055619,0.0008980791,0.0001259224,0.002462999,0.001157573,0.0005247179,0.003001892,0.00007057582],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970728,0.001355961,0.0003064973,0.0001162971,0.00001638453,0.0002527845,0.0005028889,0.00000691285,0.0003694211],"genre_scores_gemma":[0.9971303,0.0003892776,0.0005799219,0.0001773351,0.00005444898,0.0004447196,0.0008372533,0.000004634873,0.0003821472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0077763,"threshold_uncertainty_score":0.04112554,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2057925552","doi":"10.1128/jvi.06591-11","title":"Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir","year":2011,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Merck; Jewish General Hospital; Canadian Foundation for AIDS Research; Gilead Sciences","keywords":"Integrase; Dolutegravir; Biology; Integrase inhibitor; Mutagenesis; Mutation; DNA; Raltegravir; Virology; Viral replication; Reverse transcriptase; Genetics; Molecular biology; Virus; Gene; Viral load; Polymerase chain reaction","authors":[{"name":"Peter K. Quashie","is_ca":true},{"name":"Thibault Mésplède","is_ca":true},{"name":"Ying-Shan Han","is_ca":true},{"name":"Maureen Oliveira","is_ca":true},{"name":"Diane N. Singhroy","is_ca":true},{"name":"Tamio Fujiwara","is_ca":false},{"name":"Mark Underwood","is_ca":false},{"name":"Mark A. Wainberg","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03907600993030807,"gpt":0.2449276465907511,"spread":0.205851636660443,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001838731,0.0003921216,0.0002993896,0.0001766996,0.0001323434,0.0003259572,0.0003160944,0.0003934844,0.0005932675],"category_scores_gemma":[0.0002699827,0.0001417035,0.0003498784,0.0002397445,0.0001734052,0.0001102891,0.000114273,0.0005209821,0.0004792502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000238426,"about_ca_system_score_gemma":0.0001973526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00139411,"about_ca_topic_score_gemma":0.0009335068,"domain_scores_codex":[0.9998602,0.00002603658,0.00001878205,0.00002360866,0.00004850784,0.00002286768],"domain_scores_gemma":[0.9998571,0.00003225806,0.00004920311,0.00001481293,0.00001939043,0.00002724426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00009506148,0.00007359955,0.000636586,0.00002231682,0.000007364416,0.0003103267,0.00001808987,0.0002382416,0.9977326,0.00006653167,0.0000327894,0.0007664843],"study_design_scores_gemma":[0.00003707259,0.0005073409,0.01383785,0.00001468559,0.00004379995,0.003078128,0.00007757402,0.004671794,0.9751888,0.00005935646,0.002462973,0.00002055672],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967153,0.0003186053,0.001519165,0.0000509801,0.00001580984,0.00003924408,0.0007355539,0.00002439227,0.0005810165],"genre_scores_gemma":[0.9947644,0.0002796156,0.00230891,0.00003767369,0.000005675717,0.00001162744,0.001527546,0.00003849162,0.001025987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00139411,"threshold_uncertainty_score":0.002771974,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025935798","doi":"10.1371/journal.pmed.1001810","title":"Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver; Simon Fraser University; Public Health Agency of Canada","funders":"U.S. Public Health Service; National Institutes of Health; Biotechnology and Biological Sciences Research Council; World Health Organization; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation","keywords":"Drug resistance; Odds ratio; Molecular epidemiology; GenBank; Epidemiology; Virology; Medicine; Genotype; Demography; Biology; Genetics; Internal medicine","authors":[{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"José Luís Blanco","is_ca":false},{"name":"Michael R. Jordan","is_ca":false},{"name":"Jonathan Taylor","is_ca":false},{"name":"Philippe Lemey","is_ca":false},{"name":"Vici Varghese","is_ca":false},{"name":"Raph L Hamers","is_ca":false},{"name":"Silvia Bertagnolio","is_ca":false},{"name":"Tobias F. Rinke de Wit","is_ca":false},{"name":"Avelin F. Aghokeng","is_ca":false},{"name":"Jan Albert","is_ca":false},{"name":"Radko Avi","is_ca":false},{"name":"Santiago Ávila‐Ríos","is_ca":false},{"name":"Pascal Bessong","is_ca":false},{"name":"James Brooks","is_ca":true},{"name":"Charles A. Boucher","is_ca":false},{"name":"Zabrina L. Brumme","is_ca":true},{"name":"Michael P. Busch","is_ca":false},{"name":"Hermann Bussmann","is_ca":false},{"name":"Marie‐Laure Chaix","is_ca":false},{"name":"Bum Sik Chin","is_ca":false},{"name":"Toni Thomas d’Aquin","is_ca":false},{"name":"Cillian De Gascun","is_ca":false},{"name":"Anne Derache","is_ca":false},{"name":"Diane Descamps","is_ca":false},{"name":"Alaka Deshpande","is_ca":false},{"name":"Cyrille F. Djoko","is_ca":false},{"name":"Susan H. Eshleman","is_ca":false},{"name":"Hervé Fleury","is_ca":false},{"name":"Pierre Frange","is_ca":false},{"name":"Seiichiro Fujisaki","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Junko Hattori","is_ca":false},{"name":"África Holguín","is_ca":false},{"name":"Gillian Hunt","is_ca":false},{"name":"Hiroshi Ichimura","is_ca":false},{"name":"Pontiano Kaleebu","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Sasisopin Kiertiburanakul","is_ca":false},{"name":"Jérôme H. Kim","is_ca":false},{"name":"Sung Soon Kim","is_ca":false},{"name":"Yanpeng Li","is_ca":false},{"name":"Irja Lutsar","is_ca":false},{"name":"Lynn Morris","is_ca":false},{"name":"Nicaise Ndembi","is_ca":false},{"name":"Kee Peng Ng","is_ca":false},{"name":"Ramesh Paranjape","is_ca":false},{"name":"Martine Peeters","is_ca":false},{"name":"Mario Poljak","is_ca":false},{"name":"Matt A. Price","is_ca":false},{"name":"Manon Ragonnet‐Cronin","is_ca":false},{"name":"Gustavo Reyes‐Terán","is_ca":false},{"name":"Morgane Rolland","is_ca":false},{"name":"Sunee Sirivichayakul","is_ca":false},{"name":"Davey M. Smith","is_ca":false},{"name":"Marcelo A. Soares","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Deogratius Ssemwanga","is_ca":false},{"name":"Maja Stanojević","is_ca":false},{"name":"Mariane A. Stefani","is_ca":false},{"name":"Wataru Sugiura","is_ca":false},{"name":"Somnuek Sungkanuparph","is_ca":false},{"name":"Amílcar Tanuri","is_ca":false},{"name":"Kok Keng Tee","is_ca":false},{"name":"Hong-Ha M. Truong","is_ca":false},{"name":"David van de Vijver","is_ca":false},{"name":"Nicole Vidal","is_ca":false},{"name":"Chunfu Yang","is_ca":false},{"name":"Rongge Yang","is_ca":false},{"name":"Gonzalo Yebra","is_ca":false},{"name":"John P. A. Ioannidis","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2218405918892829,"gpt":0.3721868621797614,"spread":0.1503462702904785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01714548,0.001870228,0.006984915,0.005294261,0.0009045597,0.003152091,0.002115134,0.001972596,0.003777056],"category_scores_gemma":[0.01838014,0.001515395,0.03511474,0.008244184,0.000592307,0.001816751,0.001927073,0.002481126,0.0003988268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00101101,"about_ca_system_score_gemma":0.001307806,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009984693,"about_ca_topic_score_gemma":0.01046256,"domain_scores_codex":[0.9884927,0.006025897,0.001582116,0.002584935,0.0006717788,0.0006426519],"domain_scores_gemma":[0.9781469,0.01418203,0.00258313,0.003343504,0.001095986,0.0006485202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005431966,0.00003534004,0.2375497,0.003697012,0.7446977,0.0003059407,0.0001007241,0.00240446,0.000530839,0.0001411897,0.000928159,0.004176901],"study_design_scores_gemma":[0.0007713922,0.0005456985,0.1372735,0.0008397798,0.8505583,0.0005374596,0.0002565119,0.006507862,0.0003119549,0.0005991931,0.001728237,0.00007022906],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.6499385,0.3207687,0.01386287,0.001458063,0.0007650973,0.0003104406,0.01051183,0.0005144704,0.001870134],"genre_scores_gemma":[0.9843096,0.01065719,0.00255232,0.0002564628,0.0001095472,0.0002005608,0.001431092,0.00009629862,0.0003868959],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.9930151,"threshold_uncertainty_score":0.09067506,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968328048","doi":"10.1016/j.tips.2009.10.001","title":"The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters","year":2009,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Drug; Pharmacology; Antiretroviral drug; ATP-binding cassette transporter; Drug interaction; Efflux; Pharmacokinetics; Transporter; Human immunodeficiency virus (HIV); Drug metabolism; Antiretroviral therapy; Medicine; Virology; Biology; Viral load; Biochemistry","authors":[{"name":"Olena Kis","is_ca":true},{"name":"Kevin R. Robillard","is_ca":true},{"name":"Gary N. Y. Chan","is_ca":true},{"name":"Reina Bendayan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08393546633828616,"gpt":0.4171650216645466,"spread":0.3332295553262604,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009360678,0.0008239163,0.002277081,0.001463104,0.0002656013,0.00153693,0.0009661889,0.001615172,0.002792724],"category_scores_gemma":[0.0009941676,0.0002924566,0.0005133428,0.002034708,0.0007923518,0.002927602,0.0007290728,0.001985933,0.001253418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006449764,"about_ca_system_score_gemma":0.001357741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001161295,"about_ca_topic_score_gemma":0.002878837,"domain_scores_codex":[0.9996585,0.00007805218,0.0000469407,0.0000488147,0.000141581,0.00002609406],"domain_scores_gemma":[0.999162,0.0005087516,0.0001005987,0.00002059145,0.0001662668,0.00004173308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007130138,0.00005788397,0.0003031388,0.0106241,0.000119987,0.0004116415,0.00007667847,0.0005057373,0.002082721,0.007903814,0.02511076,0.9527323],"study_design_scores_gemma":[0.00002332424,0.00008591395,0.001087647,0.002264332,0.0001481035,0.002186615,0.0001547261,0.0003271643,0.0004393157,0.00739709,0.9858542,0.00003148527],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001376387,0.9980975,0.0002185939,0.0006697468,0.0001368989,0.000002077095,0.00000838055,0.000006137823,0.0007230931],"genre_scores_gemma":[0.0006838303,0.9980879,0.0003174192,0.0003211415,0.0002562137,0.000002718172,0.00001458721,9.480476e-7,0.0003151124],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002792724,"threshold_uncertainty_score":0.009342551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1995559092","doi":"10.1097/01.aids.0000232228.88511.0b","title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Didanosine; Lamivudine; Resistance mutation; Virology; Zidovudine; Abacavir; Biology; Reverse transcriptase; Drug resistance; Genotype; Stavudine; Genotyping; Reverse-transcriptase inhibitor; Virus; Sida; Genetics; Viral disease; Polymerase chain reaction; Gene; Hepatitis B virus","authors":[{"name":"Bluma Brenner","is_ca":true},{"name":"Maureen Oliveira","is_ca":true},{"name":"Florence Doualla‐Bell","is_ca":true},{"name":"Daniela Moïsi","is_ca":true},{"name":"Michel Ntemgwa","is_ca":true},{"name":"Fernando Frankel","is_ca":true},{"name":"Max Essex","is_ca":false},{"name":"Mark A. Wainberg","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01021666569478998,"gpt":0.2445065241397908,"spread":0.2342898584450008,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002699726,0.0002826112,0.0003340002,0.0001439208,0.0002356644,0.0004700258,0.0002602939,0.0002290275,0.001410764],"category_scores_gemma":[0.0003822004,0.0001802336,0.0002393119,0.0001993731,0.0001282883,0.0001730418,0.0002576772,0.0006036984,0.001058176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003818991,"about_ca_system_score_gemma":0.0002107305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00355455,"about_ca_topic_score_gemma":0.003600909,"domain_scores_codex":[0.9996337,0.00005210207,0.00004043386,0.00007049295,0.0001113172,0.00009198891],"domain_scores_gemma":[0.9995188,0.0001462162,0.00008062499,0.0001062577,0.00009606695,0.00005210115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002366591,0.00005239359,0.003686278,0.00003001082,0.00001552226,0.0001001886,0.0000914771,0.00007587364,0.9929463,0.00005714999,0.0002835038,0.002424768],"study_design_scores_gemma":[0.0001088772,0.001796434,0.1193053,0.00005729388,0.00006757955,0.00287314,0.0003043729,0.003222651,0.8583494,0.0001598489,0.01370986,0.00004524537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937143,0.0007869533,0.001710217,0.0000559577,0.00002140426,0.00008084433,0.0006954144,0.00005979079,0.002875001],"genre_scores_gemma":[0.9878682,0.0007455792,0.004483531,0.000244768,0.0000194258,0.0001326513,0.002594481,0.00004816532,0.00386322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00355455,"threshold_uncertainty_score":0.00706774,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151647473","doi":"10.1086/499364","title":"Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study","year":2006,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; University of California, San Diego; National Institute of Neurological Disorders and Stroke; University of Pittsburgh; University of Washington; Case Western Reserve University; University of Minnesota; Pfizer; Northwestern University; Biogen; University of Rochester; University of Miami; York University; Bristol-Myers Squibb; Quest Diagnostics; University of Pennsylvania; Gilead Sciences; Vanderbilt University; National Institutes of Health; Ohio State University; ACT Government; University of Southern California; Emory University; Brigham and Women's Hospital; GlaxoSmithKline","keywords":"Efavirenz; Discontinuation; Medicine; CYP2B6; Internal medicine; Interquartile range; Genotype; Gastroenterology; Pharmacogenetics; Pharmacokinetics; Population; Pharmacology; Viral load; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology; Genetics; Cytochrome P450; CYP3A4","authors":[{"name":"Heather J. Ribaudo","is_ca":false},{"name":"David W. Haas","is_ca":false},{"name":"C. Tierney","is_ca":false},{"name":"Richard B. Kim","is_ca":false},{"name":"G. Wilkinson","is_ca":false},{"name":"Roy M. Gulick","is_ca":false},{"name":"David B. Clifford","is_ca":false},{"name":"Catia Marzolini","is_ca":false},{"name":"Courtney V. Fletcher","is_ca":false},{"name":"Karen T. Tashima","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Edward P. Acosta","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08505330597271046,"gpt":0.4501052160299698,"spread":0.3650519100572593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00670086,0.0007274331,0.001174333,0.0003260128,0.0004338397,0.001018689,0.0004364806,0.001078335,0.001919943],"category_scores_gemma":[0.00940324,0.0003254424,0.0008867169,0.0008594151,0.0004045482,0.000593825,0.0003421426,0.0009248473,0.000392059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003039217,"about_ca_system_score_gemma":0.0005449638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004927109,"about_ca_topic_score_gemma":0.0006804441,"domain_scores_codex":[0.9955337,0.003267681,0.0002874925,0.0004489535,0.0003018452,0.0001603886],"domain_scores_gemma":[0.9924343,0.002878995,0.002671048,0.0008567413,0.0005611888,0.0005978743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2505703,0.003206068,0.6990254,0.0004805806,0.007929157,0.0005394382,0.0005266327,0.001077977,0.002262091,0.0003171638,0.002690586,0.03137465],"study_design_scores_gemma":[0.0701409,0.03299511,0.8822492,0.0001451551,0.005095833,0.001173485,0.0001777172,0.0024985,0.0005789449,0.0004083413,0.004471534,0.00006531523],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995878,0.001433227,0.0003849535,0.0001454,0.00002027285,0.0003034955,0.0007421235,0.00001185129,0.001080604],"genre_scores_gemma":[0.9971747,0.0004121,0.0005083211,0.0002272846,0.00007113136,0.0003860864,0.0008172917,0.000007446555,0.0003955654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00670086,"threshold_uncertainty_score":0.03543794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2053792903","doi":"10.1038/nsmb.1540","title":"Nucleic acid polymerases use a general acid for nucleotidyl transfer","year":2009,"lang":"en","type":"article","venue":"Nature Structural & Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Chemistry; Polymerase; Pyrophosphate; Deprotonation; Nucleic acid; Active site; DNA polymerase; Protonation; Stereochemistry; Biochemistry; DNA polymerase beta; Leaving group; Enzyme; DNA; Catalysis; Base excision repair; DNA repair; Organic chemistry","authors":[{"name":"Christian Castro","is_ca":false},{"name":"Eric D. Smidansky","is_ca":false},{"name":"Jamie J. Arnold","is_ca":false},{"name":"Kenneth R. Maksimchuk","is_ca":false},{"name":"Ibrahim M. Moustafa","is_ca":false},{"name":"Akira Uchida","is_ca":false},{"name":"Matthias Götte","is_ca":true},{"name":"William H. Konigsberg","is_ca":false},{"name":"Craig E. Cameron","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007258418535612243,"gpt":0.3003279623161461,"spread":0.2930695437805338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002109004,0.004512613,0.002979569,0.001858449,0.001668495,0.001519085,0.001572917,0.003597327,0.002092619],"category_scores_gemma":[0.002946525,0.00269801,0.002164765,0.0009351813,0.002111277,0.001556739,0.002117709,0.004674992,0.00810995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001059888,"about_ca_system_score_gemma":0.001482635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007867969,"about_ca_topic_score_gemma":0.00130173,"domain_scores_codex":[0.9973252,0.0007344761,0.000261883,0.000834266,0.0005379374,0.0003061904],"domain_scores_gemma":[0.9983397,0.0005457724,0.0002099979,0.0004956811,0.0001978793,0.0002109045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006580146,0.0001626623,0.0005051092,0.0009377793,0.0001015554,0.0003754098,0.0003660247,0.0007999149,0.9640437,0.005112432,0.001789815,0.02514758],"study_design_scores_gemma":[0.00008556728,0.0005087674,0.0003563046,0.00005299467,0.00007244106,0.0005595268,0.00002939003,0.0004368541,0.9629907,0.0006250325,0.03421576,0.00006670484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.2508893,0.02051173,0.6712651,0.001694285,0.002821659,0.005549962,0.002883896,0.02000365,0.02438049],"genre_scores_gemma":[0.4867472,0.01080696,0.4551252,0.002049886,0.0003057352,0.004159868,0.006215517,0.001886484,0.03270318],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004512613,"threshold_uncertainty_score":0.01115364,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2252811454","doi":"10.1097/qai.0000000000000790","title":"Brief Report","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Lamivudine; Emtricitabine; Efavirenz; Medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Chronic hepatitis; Virus","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Axel Baumgarten","is_ca":false},{"name":"Juan Berenguer","is_ca":false},{"name":"Franco Felizarta","is_ca":false},{"name":"Éric Florence","is_ca":false},{"name":"Marie-Aude Khuong-Josses","is_ca":false},{"name":"J Michael Kilby","is_ca":false},{"name":"Thomas A. Lutz","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Joaquín Portilla","is_ca":false},{"name":"Norman Roth","is_ca":false},{"name":"Deborah Jean Lee Wong","is_ca":false},{"name":"Catherine Granier","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Keith A. Pappa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0341467119659951,"gpt":0.2919896861536674,"spread":0.2578429741876723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003097389,0.0009184413,0.0008589746,0.001387352,0.00190275,0.003765437,0.00189768,0.003508731,0.5358912],"category_scores_gemma":[0.01149149,0.0004089579,0.0008879098,0.0009154202,0.0005684315,0.00192305,0.002414998,0.002727603,0.3324662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001481228,"about_ca_system_score_gemma":0.00549006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002128963,"about_ca_topic_score_gemma":0.002504337,"domain_scores_codex":[0.9977109,0.0005622556,0.0002253932,0.000419736,0.0007903919,0.000291166],"domain_scores_gemma":[0.9933134,0.000868284,0.000366789,0.0009960313,0.002706472,0.001749087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002833762,0.0001689525,0.001074196,0.0003256611,0.00002080673,0.0003644589,0.00007694971,0.00003276875,0.0002896686,0.00391514,0.8239903,0.1694577],"study_design_scores_gemma":[0.00006326067,0.00009882302,0.0007357646,0.0001875963,0.00001240803,0.0006672349,0.00007555499,0.00002374955,0.0001536455,0.001388518,0.9965845,0.000008907832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.005528856,0.02253874,0.005396092,0.07759485,0.08524779,0.002063769,0.02035238,0.001752564,0.7795249],"genre_scores_gemma":[0.02463419,0.01389464,0.00395881,0.03667843,0.01677368,0.001262168,0.01427687,0.000519091,0.8880021],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.4641088,"threshold_uncertainty_score":0.6619948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121720236","doi":"10.1056/nejmra1004180","title":"Development of Antiretroviral Drug Resistance","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; Antiretroviral drug; ANTIRETROVIRAL AGENTS; Drug; HIV drug resistance; Resistance (ecology); Virology; Antiretroviral therapy; Medicine; Computational biology; Biology; Pharmacology; Genetics; Viral load","authors":[{"name":"Mark A. Wainberg","is_ca":true},{"name":"Gerasimos J. Zaharatos","is_ca":true},{"name":"Bluma Brenner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03104493270825844,"gpt":0.2620090213942288,"spread":0.2309640886859703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009498721,0.0003096945,0.0005444018,0.0005944856,0.0004285547,0.001386272,0.0005472432,0.0007575687,0.009499253],"category_scores_gemma":[0.001875726,0.0001968598,0.0004977958,0.0003806104,0.0004153697,0.0005139486,0.0009061093,0.001507372,0.002578981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005547099,"about_ca_system_score_gemma":0.000455728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003110775,"about_ca_topic_score_gemma":0.0002725309,"domain_scores_codex":[0.998978,0.0002624397,0.00007086003,0.0001216683,0.0004079533,0.0001590642],"domain_scores_gemma":[0.9992854,0.0001578701,0.0001495057,0.00009651758,0.0001862797,0.0001244765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0002594293,0.0007388747,0.03870879,0.0009505117,0.000186247,0.00465556,0.0006602167,0.0005562276,0.1339315,0.03273191,0.02719149,0.7594293],"study_design_scores_gemma":[0.000170321,0.003172895,0.05605258,0.0006220452,0.0002219231,0.03179212,0.0005016606,0.00260936,0.09489106,0.008542272,0.8013531,0.00007064526],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4970768,0.1068212,0.03081207,0.0132144,0.002566603,0.00157577,0.003973975,0.001417231,0.3425419],"genre_scores_gemma":[0.9001397,0.03002168,0.009834867,0.005452523,0.0003743692,0.0003328178,0.001854582,0.00008104582,0.05190839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009499253,"threshold_uncertainty_score":0.03177816,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2510140996","doi":"10.1016/s2352-3018(16)30091-1","title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Medicine; Efavirenz; Dolutegravir; Adverse effect; Meta-analysis; Odds ratio; Raltegravir; Viral load; Internal medicine; Indinavir; MEDLINE; Confidence interval; Antiretroviral therapy; Human immunodeficiency virus (HIV); Family medicine","authors":[{"name":"Steve Kanters","is_ca":true},{"name":"Marco Vitória","is_ca":false},{"name":"Meg Doherty","is_ca":false},{"name":"M. Eugenia Socías","is_ca":false},{"name":"Nathan Ford","is_ca":false},{"name":"Jamie I. Forrest","is_ca":true},{"name":"Evan Popoff","is_ca":false},{"name":"Nick Bansback","is_ca":true},{"name":"Sabin Nsanzimana","is_ca":false},{"name":"Kristian Thorlund","is_ca":false},{"name":"Edward J. Mills","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1560874485520365,"gpt":0.3874352813437313,"spread":0.2313478327916948,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01063019,0.002610997,0.01848992,0.004028785,0.000497118,0.002570223,0.002241291,0.002109199,0.003179263],"category_scores_gemma":[0.02959312,0.00110206,0.02857071,0.004353574,0.000700855,0.001749337,0.001349012,0.002174021,0.0002471212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002529863,"about_ca_system_score_gemma":0.002453797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006554695,"about_ca_topic_score_gemma":0.01367204,"domain_scores_codex":[0.992174,0.003830957,0.002094642,0.0007942119,0.0008690172,0.0002372188],"domain_scores_gemma":[0.9814107,0.01485171,0.002247721,0.0004978626,0.0007935348,0.0001984338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00361314,0.00003811927,0.002478869,0.2550422,0.7255484,0.00008366952,0.00005948751,0.0004461002,0.0001983095,0.0001270555,0.0003821014,0.01198263],"study_design_scores_gemma":[0.0008966935,0.0002215368,0.002140983,0.009846509,0.9856164,0.00006461456,0.00003351044,0.0001342303,0.00008305097,0.0001554894,0.0007866644,0.00002017465],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005090992,0.9936928,0.000407231,0.0000882259,0.000145433,0.0001395049,0.000270441,0.00001579272,0.0001496193],"genre_scores_gemma":[0.1730363,0.8227252,0.00186399,0.000737295,0.0002854831,0.0004306267,0.0006010993,0.00002222382,0.0002978031],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01848992,"threshold_uncertainty_score":0.0562185,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135892517","doi":"10.1097/00002030-200106150-00003","title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"HIV Legal Network; St. Paul's Hospital","funders":"Institut National Du Cancer","keywords":"Nevirapine; Zidovudine; Medicine; Didanosine; Regimen; Internal medicine; Viral load; Reverse-transcriptase inhibitor; Immunology; Logistic regression; Sida; Lentivirus; Human immunodeficiency virus (HIV); Gastroenterology; Pharmacology; Virology; Antiretroviral therapy; Viral disease","authors":[{"name":"Agnes I. Veldkamp","is_ca":false},{"name":"Gerrit Jan Weverling","is_ca":false},{"name":"Joep M. A. Lange","is_ca":false},{"name":"Julio Montaner","is_ca":true},{"name":"Peter Reiss","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"David B. Hall","is_ca":false},{"name":"Jos H. Beijnen","is_ca":false},{"name":"Richard M. W. Hoetelmans","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01383608118583745,"gpt":0.2546148819587632,"spread":0.2407788007729257,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005937263,0.000160361,0.0003222306,0.000184878,0.000143989,0.0003847101,0.0001179541,0.0003461246,0.001382425],"category_scores_gemma":[0.003114835,0.0001276775,0.0002145227,0.000217037,0.0001436981,0.0001979995,0.0001297594,0.000424985,0.0001252354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001062474,"about_ca_system_score_gemma":0.00013824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004576855,"about_ca_topic_score_gemma":0.0005273314,"domain_scores_codex":[0.9996473,0.0001598416,0.00002392883,0.00005003823,0.0000726903,0.0000462227],"domain_scores_gemma":[0.9979615,0.0008426103,0.0008499587,0.00008720509,0.00008452642,0.0001740231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004311482,0.0002272103,0.9760107,0.00005595154,0.0003458064,0.0001538335,0.00007982658,0.0004432019,0.005214683,0.00002935158,0.0001194452,0.01300843],"study_design_scores_gemma":[0.00007126421,0.001057258,0.9970041,0.000007657211,0.00007990641,0.0004613534,0.00003115964,0.0006690217,0.0004320233,0.00003542419,0.0001462116,0.000004616958],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999404,0.0002714545,0.0000636957,0.00002407004,0.000002091401,0.000003396791,0.00003400981,0.000004582282,0.0001927563],"genre_scores_gemma":[0.9997166,0.00005622338,0.00006761169,0.00001831454,0.000007807476,0.000002678167,0.0000426037,0.000001385196,0.00008667697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001382425,"threshold_uncertainty_score":0.004624724,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2887935769","doi":"10.1093/infdis/jiy479","title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health; Harvard University Center for AIDS Research; Harvard University; Fred Hutchinson Cancer Research Center; Janssen Pharmaceuticals; Gilead Sciences; Styrelsen för Internationellt Utvecklingssamarbete; Center for AIDS Research, University of Washington; AIDS Healthcare Foundation; GlaxoSmithKline; Canadian Institutes of Health Research; University of Washington; amfAR, The Foundation for AIDS Research","keywords":"Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Antiretroviral drug; Intensive care medicine; Immunology; Viral load","authors":[{"name":"Golnaz Namazi","is_ca":false},{"name":"Jesse Fajnzylber","is_ca":false},{"name":"Evgenia Aga","is_ca":false},{"name":"Ronald J. Bosch","is_ca":false},{"name":"Edward P. Acosta","is_ca":false},{"name":"Radwa Sharaf","is_ca":false},{"name":"Wendy Hartogensis","is_ca":false},{"name":"Jeffrey M. Jacobson","is_ca":false},{"name":"Elizabeth Connick","is_ca":false},{"name":"Paul A. Volberding","is_ca":false},{"name":"Daniel J. Skiest","is_ca":false},{"name":"David M. Margolis","is_ca":false},{"name":"Michael C. Sneller","is_ca":false},{"name":"Susan J. Little","is_ca":false},{"name":"Sara Gianella","is_ca":false},{"name":"Davey M. Smith","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Roy M. Gulick","is_ca":false},{"name":"John W. Mellors","is_ca":false},{"name":"Vikram Mehraj","is_ca":true},{"name":"Rajesh T. Gandhi","is_ca":false},{"name":"Ronald T. Mitsuyasu","is_ca":false},{"name":"Robert T. Schooley","is_ca":false},{"name":"Keith Henry","is_ca":false},{"name":"Pablo Tebas","is_ca":false},{"name":"Steven G. Deeks","is_ca":false},{"name":"Tae‐Wook Chun","is_ca":false},{"name":"Ann C. Collier","is_ca":false},{"name":"Jean‐Pierre Routy","is_ca":true},{"name":"Frederick Hecht","is_ca":false},{"name":"Bruce D. Walker","is_ca":false},{"name":"Jonathan Z. Li","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01985700599769024,"gpt":0.3328229900501709,"spread":0.3129659840524807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004057661,0.000441111,0.0006748681,0.001409328,0.0005119094,0.001221217,0.0005676762,0.0007365366,0.002762011],"category_scores_gemma":[0.005305042,0.0002385465,0.0004690196,0.001187776,0.0003846333,0.0005581884,0.0008275132,0.0003191701,0.0002065971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003288976,"about_ca_system_score_gemma":0.0007461484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001450865,"about_ca_topic_score_gemma":0.002890896,"domain_scores_codex":[0.9982123,0.0008400552,0.0002751603,0.0002608674,0.0002706764,0.0001409436],"domain_scores_gemma":[0.9952824,0.001230951,0.002255863,0.0003746962,0.000538527,0.0003176495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009307245,0.0003210364,0.968058,0.0008433233,0.00195235,0.0002223251,0.0004331589,0.00007196966,0.001096249,0.0001222804,0.001244678,0.01632745],"study_design_scores_gemma":[0.001987266,0.002730309,0.9860119,0.0003941186,0.002174338,0.0007918937,0.0004744582,0.0002078549,0.0005444918,0.00008566079,0.004572743,0.00002479492],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923815,0.004291961,0.0001458229,0.00006100965,0.00001304512,0.0003936773,0.001590266,0.00000860316,0.001114136],"genre_scores_gemma":[0.9944127,0.001010387,0.0004472188,0.00014861,0.00004429535,0.0003333552,0.003140595,0.000005801521,0.0004570395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004057661,"threshold_uncertainty_score":0.02145922,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135417699","doi":"10.1086/650002","title":"Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials","year":2010,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Raltegravir; Medicine; Antiretroviral therapy; Internal medicine; Integrase inhibitor; Pharmacotherapy; Drug; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Virology","authors":[{"name":"Roy T. Steigbigel","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Hedy Teppler","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Jürgen K. Rockstroh","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Martin Markowitz","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Mona Loutfy","is_ca":true},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Jeffrey L. Lennox","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Jing Zhao","is_ca":false},{"name":"Hong Wan","is_ca":false},{"name":"Rand R. Rhodes","is_ca":false},{"name":"Kim M. Strohmaier","is_ca":false},{"name":"Richard J. O. Barnard","is_ca":false},{"name":"Robin Isaacs","is_ca":false},{"name":"Bach‐Yen Nguyen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03522055684703406,"gpt":0.353666942293186,"spread":0.3184463854461519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001206565,0.0005349756,0.001501146,0.000246346,0.0002104905,0.000623355,0.0004794955,0.0005925766,0.001435187],"category_scores_gemma":[0.0009159668,0.0003103553,0.0007038601,0.0002479616,0.0003775769,0.0005797219,0.0002195948,0.001567687,0.0002721364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003694908,"about_ca_system_score_gemma":0.0003949853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003061602,"about_ca_topic_score_gemma":0.001196521,"domain_scores_codex":[0.9995097,0.0002888748,0.00003192608,0.00005456913,0.00004942894,0.00006544387],"domain_scores_gemma":[0.9994977,0.0001199601,0.0001420188,0.00004287538,0.00002747541,0.0001699381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.618381,0.03110464,0.008694476,0.001034083,0.002436833,0.0003336042,0.0002399391,0.003041294,0.0549902,0.0002583203,0.001743957,0.2777416],"study_design_scores_gemma":[0.3464483,0.5898989,0.04747626,0.0001205376,0.001346278,0.0006747732,0.00008480249,0.002277014,0.008094592,0.0001948677,0.003304963,0.00007860109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956971,0.002977261,0.0001894457,0.0001474066,0.0000249801,0.0001086967,0.0001417034,0.00003408123,0.0006792754],"genre_scores_gemma":[0.9970471,0.001182291,0.0005898666,0.0001821687,0.0000835261,0.0001230754,0.0003345082,0.00001024023,0.0004472726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001501146,"threshold_uncertainty_score":0.006380975,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1674196795","doi":"10.1016/s1473-3099(15)00152-8","title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Maple Leaf Medical Clinic","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Efavirenz; Emtricitabine; Regimen; Medicine; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Raltegravir; Reverse-transcriptase inhibitor; Pharmacology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"David A. Margolis","is_ca":false},{"name":"Cynthia Brinson","is_ca":false},{"name":"Graham Smith","is_ca":true},{"name":"Jerome De Vente","is_ca":false},{"name":"Debbie Hagins","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Sandy Griffith","is_ca":false},{"name":"M H St Clair","is_ca":false},{"name":"Marita Stevens","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Britt Stancil","is_ca":false},{"name":"M Bomar","is_ca":false},{"name":"Krischan J Hudson","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01747817052545608,"gpt":0.2684220902275357,"spread":0.2509439197020796,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001824946,0.002061809,0.003264156,0.0005239437,0.0004300503,0.001309852,0.001115772,0.002193461,0.007640004],"category_scores_gemma":[0.001942805,0.0008444641,0.001784746,0.0004635915,0.001524565,0.001710504,0.0005351861,0.004871452,0.001775252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008360592,"about_ca_system_score_gemma":0.001057435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001305674,"about_ca_topic_score_gemma":0.002783219,"domain_scores_codex":[0.9992566,0.0004056328,0.00003379124,0.0001154452,0.00004488132,0.0001435598],"domain_scores_gemma":[0.9990501,0.0003245081,0.0001375997,0.00008002626,0.00004576977,0.0003620934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9768401,0.004887762,0.0002634622,0.0003772976,0.0003629601,0.0000262616,0.00005788606,0.0002732007,0.001886564,0.00009489217,0.0005229944,0.01440646],"study_design_scores_gemma":[0.9348513,0.06311804,0.0008358406,0.00002936858,0.0001673024,0.00002725098,0.00002270103,0.0002001996,0.0002184125,0.0001110561,0.0004048219,0.00001376086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878783,0.004084983,0.0006281563,0.0007005479,0.0006151249,0.002088688,0.001019645,0.0002060671,0.002778537],"genre_scores_gemma":[0.9829999,0.003747736,0.001667569,0.001343084,0.000548697,0.00238781,0.001345883,0.00005367216,0.005905673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007640004,"threshold_uncertainty_score":0.02555835,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}